1
|
Rieu P, Beretta VM, Caselli F, Thévénon E, Lucas J, Rizk M, Franchini E, Caporali E, Paleni C, Nanao MH, Kater MM, Dumas R, Zubieta C, Parcy F, Gregis V. The ALOG domain defines a family of plant-specific transcription factors acting during Arabidopsis flower development. Proc Natl Acad Sci U S A 2024; 121:e2310464121. [PMID: 38412122 DOI: 10.1073/pnas.2310464121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 12/05/2023] [Indexed: 02/29/2024] Open
Abstract
The ALOG (Arabidopsis LIGHT-DEPENDENT SHORT HYPOCOTYLS 1 (LSH1) and Oryza G1) proteins are conserved plant-specific Transcription Factors (TFs). They play critical roles in the development of various plant organs (meristems, inflorescences, floral organs, and nodules) from bryophytes to higher flowering plants. Despite the fact that the first members of this family were originally discovered in Arabidopsis, their role in this model plant has remained poorly characterized. Moreover, how these transcriptional regulators work at the molecular level is unknown. Here, we study the redundant function of the ALOG proteins LSH1,3,4 from Arabidopsis. We uncover their role in the repression of bract development and position them within a gene regulatory network controlling this process and involving the floral regulators LEAFY, BLADE-ON-PETIOLE, and PUCHI. Next, using in vitro genome-wide studies, we identified the conserved DNA motif bound by ALOG proteins from evolutionarily distant species (the liverwort Marchantia polymorpha and the flowering plants Arabidopsis, tomato, and rice). Resolution of the crystallographic structure of the ALOG DNA-binding domain in complex with DNA revealed the domain is a four-helix bundle with a disordered NLS and a zinc ribbon insertion between helices 2 and 3. The majority of DNA interactions are mediated by specific contacts made by the third alpha helix and the NLS. Taken together, this work provides the biochemical and structural basis for DNA-binding specificity of an evolutionarily conserved TF family and reveals its role as a key player in Arabidopsis flower development.
Collapse
Affiliation(s)
- Philippe Rieu
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, Centre national de la recherche scientifique, Commissariat à l'énergie atomique et aux énergies alternatives, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Département de Biologie Structurale et Cellulaire intégrée, Grenoble F-38054, France
| | | | - Francesca Caselli
- Dipartimento di Bioscienze, Università degli Studi di Milano, Milano 20133, Italy
| | - Emmanuel Thévénon
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, Centre national de la recherche scientifique, Commissariat à l'énergie atomique et aux énergies alternatives, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Département de Biologie Structurale et Cellulaire intégrée, Grenoble F-38054, France
| | - Jérémy Lucas
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, Centre national de la recherche scientifique, Commissariat à l'énergie atomique et aux énergies alternatives, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Département de Biologie Structurale et Cellulaire intégrée, Grenoble F-38054, France
| | - Mahmoud Rizk
- Structural Biology Group, European Synchrotron Radiation Facility, Grenoble 38000, France
| | - Emanuela Franchini
- Dipartimento di Bioscienze, Università degli Studi di Milano, Milano 20133, Italy
| | - Elisabetta Caporali
- Dipartimento di Bioscienze, Università degli Studi di Milano, Milano 20133, Italy
| | - Chiara Paleni
- Dipartimento di Bioscienze, Università degli Studi di Milano, Milano 20133, Italy
| | - Max H Nanao
- Structural Biology Group, European Synchrotron Radiation Facility, Grenoble 38000, France
| | - Martin M Kater
- Dipartimento di Bioscienze, Università degli Studi di Milano, Milano 20133, Italy
| | - Renaud Dumas
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, Centre national de la recherche scientifique, Commissariat à l'énergie atomique et aux énergies alternatives, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Département de Biologie Structurale et Cellulaire intégrée, Grenoble F-38054, France
| | - Chloe Zubieta
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, Centre national de la recherche scientifique, Commissariat à l'énergie atomique et aux énergies alternatives, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Département de Biologie Structurale et Cellulaire intégrée, Grenoble F-38054, France
| | - François Parcy
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, Centre national de la recherche scientifique, Commissariat à l'énergie atomique et aux énergies alternatives, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Département de Biologie Structurale et Cellulaire intégrée, Grenoble F-38054, France
| | - Veronica Gregis
- Dipartimento di Bioscienze, Università degli Studi di Milano, Milano 20133, Italy
| |
Collapse
|
2
|
Lievre L, Dupont V, Kanagaratnam L, Faroux L, Debrumetz A, Rieu P, Wynckel A. Urine-to-plasma creatinine ratio and fractional excretion of urea performance in acute-on-chronic kidney disease patients. J Nephrol 2023; 36:2661-2663. [PMID: 37402076 DOI: 10.1007/s40620-023-01700-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 06/09/2023] [Indexed: 07/05/2023]
Affiliation(s)
- Loïc Lievre
- Department of Nephrology, University Hospital of Reims, Reims, France.
- French Intensive Care Renal Network (FIRN), Reims, France.
| | - Vincent Dupont
- Department of Nephrology, University Hospital of Reims, Reims, France
- French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT), Reims, France
| | | | - Laurent Faroux
- Department of Cardiology, University Hospital of Reims, Reims, France
| | - Alexandre Debrumetz
- Department of Nephrology, University Hospital of Reims, Reims, France
- French Intensive Care Renal Network (FIRN), Reims, France
| | - Philippe Rieu
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Alain Wynckel
- Department of Nephrology, University Hospital of Reims, Reims, France
- French Intensive Care Renal Network (FIRN), Reims, France
| |
Collapse
|
3
|
Rieu P, Arnoux-Courseaux M, Tichtinsky G, Parcy F. Thinking outside the F-box: how UFO controls angiosperm development. New Phytol 2023; 240:945-959. [PMID: 37664990 DOI: 10.1111/nph.19234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 07/19/2023] [Indexed: 09/05/2023]
Abstract
The formation of inflorescences and flowers is essential for the successful reproduction of angiosperms. In the past few decades, genetic studies have identified the LEAFY transcription factor and the UNUSUAL FLORAL ORGANS (UFO) F-box protein as two major regulators of flower development in a broad range of angiosperm species. Recent research has revealed that UFO acts as a transcriptional cofactor, redirecting the LEAFY floral regulator to novel cis-elements. In this review, we summarize the various roles of UFO across species, analyze past results in light of new discoveries and highlight the key questions that remain to be solved.
Collapse
Affiliation(s)
- Philippe Rieu
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, CNRS, CEA, INRAE, IRIG-DBSCI-LPCV, 17 ave des martyrs, F-38054, Grenoble, France
| | - Moïra Arnoux-Courseaux
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, CNRS, CEA, INRAE, IRIG-DBSCI-LPCV, 17 ave des martyrs, F-38054, Grenoble, France
| | - Gabrielle Tichtinsky
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, CNRS, CEA, INRAE, IRIG-DBSCI-LPCV, 17 ave des martyrs, F-38054, Grenoble, France
| | - François Parcy
- Laboratoire Physiologie Cellulaire et Végétale, Université Grenoble Alpes, CNRS, CEA, INRAE, IRIG-DBSCI-LPCV, 17 ave des martyrs, F-38054, Grenoble, France
| |
Collapse
|
4
|
Courbebaisse M, Bourmaud A, Souberbielle JC, Sberro-Soussan R, Moal V, Le Meur Y, Kamar N, Albano L, Thierry A, Dantal J, Danthu C, Moreau K, Morelon E, Heng AE, Bertrand D, Arzouk N, Perrin P, Morin MP, Rieu P, Presne C, Grimbert P, Ducloux D, Büchler M, Le Quintrec M, Ouali N, Pernin V, Bouvier N, Durrbach A, Alamartine E, Randoux C, Besson V, Hazzan M, Pages J, Colas S, Piketty ML, Friedlander G, Prié D, Alberti C, Thervet E. Nonskeletal and skeletal effects of high doses versus low doses of vitamin D 3 in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial. Am J Transplant 2023; 23:366-376. [PMID: 36695682 DOI: 10.1016/j.ajt.2022.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 12/02/2022] [Accepted: 12/02/2022] [Indexed: 01/11/2023]
Abstract
Vitamin D sufficiency is associated with a reduced risk of fractures, diabetes mellitus, cardiovascular events, and cancers, which are frequent complications after renal transplantation. The VITALE (VITamin D supplementation in renAL transplant recipients) study is a multicenter double-blind randomized trial, including nondiabetic adult renal transplant recipients with serum 25-hydroxy vitamin D (25(OH) vitamin D) levels of <30 ng/mL, which is randomized 12 to 48 months after transplantation to receive high (100 000 IU) or low doses (12 000 IU) of cholecalciferol every 2 weeks for 2 months and then monthly for 22 months. The primary outcome was a composite endpoint, including diabetes mellitus, major cardiovascular events, cancer, and death. Of 536 inclusions (50.8 [13.7] years, 335 men), 269 and 267 inclusions were in the high-dose and low-dose groups, respectively. The serum 25(OH) vitamin D levels increased by 23 versus 6 ng/mL in the high-dose and low-dose groups, respectively (P < .0001). In the intent-to-treat analysis, 15% versus 16% of the patients in the high-dose and low-dose groups, respectively, experienced a first event of the composite endpoint (hazard ratio, 0.94 [0.60-1.48]; P = .78), whereas 1% and 4% of patients in the high-dose and low-dose groups, respectively, experienced an incident symptomatic fracture (odds ratio, 0.24 [0.07-0.86], P = .03). The incidence of adverse events was similar between the groups. After renal transplantation, high doses of cholecalciferol are safe but do not reduce extraskeletal complications (trial registration: ClinicalTrials.gov; identifier: NCT01431430).
Collapse
Affiliation(s)
- Marie Courbebaisse
- Paris University; Physiology Department, European Georges-Pompidou Hospital, APHP; INSERM U1151. Paris, France.
| | - Aurelie Bourmaud
- APHP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Epidémiologie Clinique, Inserm, CIC 1426, F-75019 Paris, France; Université de Paris, ECEVE UMR 1123, INSERM. F-75010 Paris, France
| | - Jean-Claude Souberbielle
- Service des explorations fonctionnelles hôpital Necker-Enfants Malades, DMU Biophygen, GHU Centre Université de Paris APHP. Paris, France
| | - Rebecca Sberro-Soussan
- Université de Paris; Service de Transplantation Rénale et Néphrologie, Hôpital Necker Enfant Malades, APHP. Paris, France
| | - Valérie Moal
- Aix-Marseille Université - AP-HM - Hôpital Conception - Centre de Néphrologie et Transplantation Rénale. Marseille, France
| | - Yannick Le Meur
- Department of Nephrology, CHU de Brest; UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, Labex IGO. Brest, France
| | - Nassim Kamar
- Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, INSERM U1043, IFR -BMT, University Paul Sabatier. Toulouse, France
| | - Laetitia Albano
- Service de Transplantation Rénale, CHU de Nice. Nice, France
| | - Antoine Thierry
- Service de Néphrologie, INSERM U1082 et Fédération Hospitalo-Universitaire BIOSUPORT. Poitiers, France
| | - Jacques Dantal
- CRTI (Centre de Recherche en Transplantation et Immunologie) INSERM UMR1064, Université de Nantes, Centre Hospitalier Universitaire de Nantes. Nantes, France
| | - Clément Danthu
- Department of Nephrology, Limoges University hospital; UMR INSERM 1092, RESINFIT, Limoges University hospital 2. Limoges, France
| | - Karine Moreau
- Unité de transplantation rénale, Hôpital Pellegrin, CHU de Bordeaux. Bordeaux, France
| | - Emmanuel Morelon
- Service de transplantation, néphrologie et immunologie clinique, Hôpital Edouard Herriot, Hospices Civils de Lyon; INSERM U1111, Université Claude Bernard Lyon1. Lyon, France
| | - Anne-Elisabeth Heng
- Service de Néphrologie, Dialyse, Transplantation, CHU de Clermont-Ferrand; Université Clermont Auvergne. F-63000 Clermont-Ferrand, France
| | - Dominique Bertrand
- Nephrology, dialysis and kidney transplantation, Rouen University Hospital. Rouen, France
| | - Nadia Arzouk
- Service de Transplantation Rénale, hôpital La Pitié-Salpétrière, APHP. Paris, France
| | - Peggy Perrin
- Department of Nephrology and Transplantation, Strasbourg University Hospital; Fédération de Médecine Translationnelle, INSERM U1109, LabEx TRANSPLANTEX. Strasbourg, France
| | | | - Philippe Rieu
- Division of Nephrology, Reims university hospital, CRNS UMR 7369 MEDyC laboratory. Reims, France
| | - Claire Presne
- Nephrology Internal Medicine Dialysis Transplantation Department, Amiens University Hospital. Amiens France
| | - Philippe Grimbert
- Nephrology and Transplant Department, CHU Henri-Mondor, APHP; Université Paris Est Créteil, INSERM U955. Paris, France
| | - Didier Ducloux
- Department of Nephrology, CHU Besançon. Besançon, France
| | - Matthias Büchler
- Department of Nephrology and Transplantation, CHU Tours; University of Tours, EA4245 Transplantation, Immunology, Inflammation; FHU SUPORT. Tours, France
| | | | - Nacéra Ouali
- Nephrology department, SINRA, Hôpital Tenon. Paris, France
| | - Vincent Pernin
- University of Montpellier, Department of Nephrology, Dialysis and Transplantation, Montpellier University hospital; Institute for Regenerative Medicine & Biotherapy (IRMB), INSERM U1183. Montpellier, France
| | - Nicolas Bouvier
- Service de Néphrologie-Dialyse-Transplantation, CHU Caen Normandie; Université de Caen Normandie. Caen, France
| | - Antoine Durrbach
- Université Paris Saclay, France; INSERM UMR 1186, Gustave Roussy. Villejuif, France; Nephrology Department, Bicêtre Hospital APHP. Le Kremlin-Bicêtre, France
| | - Eric Alamartine
- CHU de Saint Etienne et CIRI - INSERM U1111 - CNRS UMR5308 - ENS Lyon/UCBL1/Université St Etienne. Saint Etienne, France
| | - Christine Randoux
- Service de Néphrologie, CHU Bichat Claude Bernard, APHP.Nord. Paris, France
| | - Virginie Besson
- Service de Néphrologie-Dialyse-transplantation, CHU d'Angers. Angers, France
| | - Marc Hazzan
- Université de Lille, INSERM, CHU Lille, U1286 - Infinite - Institute for Translational Research in Inflammation. F-59000 Lille, France
| | - Justine Pages
- APHP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Epidémiologie Clinique, INSERM, CIC 1426. F-75019 Paris, France
| | - Sandra Colas
- Unité de Recherche Clinique Necker-Cochin, APHP. Paris, France
| | - Marie-Liesse Piketty
- Service des explorations fonctionnelles hôpital Necker-Enfants Malades, DMU Biophygen, GHU Centre Université de Paris APHP. Paris, France
| | | | - Dominique Prié
- Université de Paris; INSERM U1151, service des explorations fonctionnelles hôpital Necker-Enfants Malades, DMU Biophygen, GHU Centre Université de Paris APHP. Paris, France
| | - Corinne Alberti
- APHP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Epidémiologie Clinique, Inserm, CIC 1426, F-75019 Paris, France; Université de Paris, ECEVE UMR 1123, INSERM. F-75010 Paris, France
| | - Eric Thervet
- Paris University; Nephrology Department, European Georges-Pompidou Hospital, APHP; INSERM UMR 970, Paris Cardiovascular Research Center. Paris, France
| |
Collapse
|
5
|
Rieu P, Turchi L, Thévenon E, Zarkadas E, Nanao M, Chahtane H, Tichtinsky G, Lucas J, Blanc-Mathieu R, Zubieta C, Schoehn G, Parcy F. The F-box protein UFO controls flower development by redirecting the master transcription factor LEAFY to new cis-elements. Nat Plants 2023; 9:315-329. [PMID: 36732360 DOI: 10.1038/s41477-022-01336-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 12/20/2022] [Indexed: 06/18/2023]
Abstract
In angiosperms, flower development requires the combined action of the transcription factor LEAFY (LFY) and the ubiquitin ligase adaptor F-box protein, UNUSUAL FLORAL ORGANS (UFO), but the molecular mechanism underlying this synergy has remained unknown. Here we show in transient assays and stable transgenic plants that the connection to ubiquitination pathways suggested by the UFO F-box domain is mostly dispensable. On the basis of biochemical and genome-wide studies, we establish that UFO instead acts by forming an active transcriptional complex with LFY at newly discovered regulatory elements. Structural characterization of the LFY-UFO-DNA complex by cryo-electron microscopy further demonstrates that UFO performs this function by directly interacting with both LFY and DNA. Finally, we propose that this complex might have a deep evolutionary origin, largely predating flowering plants. This work reveals a unique mechanism of an F-box protein directly modulating the DNA binding specificity of a master transcription factor.
Collapse
Affiliation(s)
- Philippe Rieu
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
| | - Laura Turchi
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
- Translational Innovation in Medicine and Complexity, Université Grenoble Alpes, CNRS, Grenoble, France
| | - Emmanuel Thévenon
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
| | - Eleftherios Zarkadas
- IBS, Université Grenoble Alpes, CNRS, CEA, Grenoble, France
- EMBL, ISBG, Université Grenoble Alpes, CNRS, CEA, Grenoble, France
| | - Max Nanao
- Structural Biology Group, European Synchrotron Radiation Facility, Grenoble, France
| | - Hicham Chahtane
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
- Green Mission Pierre Fabre, Conservatoire Botanique Pierre Fabre, Institut de Recherche Pierre Fabre, Soual, France
| | - Gabrielle Tichtinsky
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
| | - Jérémy Lucas
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
| | - Romain Blanc-Mathieu
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
| | - Chloe Zubieta
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France
| | - Guy Schoehn
- IBS, Université Grenoble Alpes, CNRS, CEA, Grenoble, France
| | - François Parcy
- Laboratoire Physiologie Cellulaire et Végétale, IRIG-DBSCI-LPCV, Université Grenoble Alpes, CEA, CNRS, INRAE, Grenoble, France.
| |
Collapse
|
6
|
Pellé G, Jalal Eddine A, Rieu P, Attias J, Fay S, Hertig A. Success of Pregnancy in a Patient on High-Volume Hemodiafiltration with Citrate-Acidified Dialysate. Case Rep Nephrol Dial 2023; 13:15-19. [PMID: 37013153 PMCID: PMC10066502 DOI: 10.1159/000528725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 10/29/2022] [Indexed: 04/03/2023] Open
Abstract
Although pregnancy in dialysis patients is rare, recent reports in the literature have shown improvement in pregnancy outcome in this population. Increasing doses of dialysis have led to improvement in fetal prognosis, but recommendations are still lacking, and there are few documented reports of pregnant woman on high-volume online hemodiafiltration. Here, we report the first successful pregnancy in a 28-year-old patient on daily high-volume online post-dilution hemodiafiltration with a citrate dialysate. At 37 weeks and 1 day, she delivered a healthy 2.3 kg baby that did not require neonatal intensive care. This case report suggests that hemodiafiltration with a dialysate acidified with citrate is safe in pregnancy. Further reports and a registry are necessary to confirm that high-volume online hemodiafiltration with a citrate dialysate should be the preferred dialysis modality in pregnant women.
Collapse
Affiliation(s)
- Gaëlle Pellé
- Department of Nephrology, Foch Hospital, Suresnes, France
| | | | | | | | - Stephanie Fay
- Department Gynecology, Foch Hospital, Suresnes, France
| | | |
Collapse
|
7
|
Abstract
Like in other angiosperms, the development of flowers in Arabidopsis starts right after the floral transition, when the shoot apical meristem (SAM) stops producing leaves and makes flowers instead. On the flanks of the SAM emerge the flower meristems (FM) that will soon differentiate into the four main floral organs, sepals, petals, stamens, and pistil, stereotypically arranged in concentric whorls. Each phase of flower development-floral transition, floral bud initiation, and floral organ development-is under the control of specific gene networks. In this chapter, we describe these different phases and the gene regulatory networks involved, from the floral transition to the floral termination.
Collapse
Affiliation(s)
- Hicham Chahtane
- CNRS, Université Grenoble Alpes, CEA, INRAE, IRIG, BIG-LPCV, Grenoble, France
- Institut de Recherche Pierre Fabre, Green Mission Pierre Fabre, Conservatoire Botanique Pierre Fabre, Soual, France
| | - Xuelei Lai
- CNRS, Université Grenoble Alpes, CEA, INRAE, IRIG, BIG-LPCV, Grenoble, France
- Huazhong Agricultural University, National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory, Wuhan, China
| | | | - Philippe Rieu
- CNRS, Université Grenoble Alpes, CEA, INRAE, IRIG, BIG-LPCV, Grenoble, France
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | | | - Coralie Cancé
- CNRS, Université Grenoble Alpes, CEA, INRAE, IRIG, BIG-LPCV, Grenoble, France
| | - Claudius Marondedze
- CNRS, Université Grenoble Alpes, CEA, INRAE, IRIG, BIG-LPCV, Grenoble, France
- Department of Biochemistry, Faculty of Medicine, Midlands State University, Senga, Gweru, Zimbabwe
| | - François Parcy
- CNRS, Université Grenoble Alpes, CEA, INRAE, IRIG, BIG-LPCV, Grenoble, France.
| |
Collapse
|
8
|
Hutin S, Blanc-Mathieu R, Rieu P, Parcy F, Lai X, Zubieta C. Identification of Plant Transcription Factor DNA-Binding Sites Using seq-DAP-seq. Methods Mol Biol 2023; 2698:119-145. [PMID: 37682473 DOI: 10.1007/978-1-0716-3354-0_9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2023]
Abstract
The identification of genome-wide transcription factor binding sites (TFBS) is a critical step in deciphering gene and transcriptional regulatory networks. However, determining the genome-wide binding of specific TFs or TF complexes remains a technical challenge. DNA affinity purification sequencing (DAP-seq) and modifications such as sequential DAP-seq (seq-DAP-seq) are robust in vitro methods for mapping individual TF or TF complex binding sites in a genome-wide manner. DAP-seq protocols use a genomic DNA (gDNA) library from any target organism with or without amplification, allowing the determination of TF binding on naked or endogenously modified DNA, respectively. As a first step, the gDNA is fragmented to ~200 bp, end-repaired, and sequencing adaptors are added. This gDNA library can be used directly or an amplification step may be performed to remove DNA modifications such as cytosine methylation. DNA libraries are then incubated with an affinity-tagged TF or TF- complex immobilized on magnetic beads. The TF or TF complex of interest is generally produced using recombinant protein expression and purified prior to DNA affinity purification. After incubation of the DNA library with the immobilized TF of interest, multiple wash steps are performed to reduce non-specific DNA binding and the TF-DNA complexes eluted. The eluted DNA is PCR-amplified and sequenced using next-generation sequencing. The resulting sequence reads are mapped to the corresponding reference genome, identifying direct potential bound regions and binding sites of the TF or TF complex of interest. Predictive TFBS models are generated from the bound regions using downstream bioinformatics analysis pipelines. Here, we present a detailed protocol outlining the steps required for seq-DAP-seq of a heterooligomeric TF complex (Fig. 1) and briefly describe the downstream bioinformatics pipeline used to develop a robust TFBS model from sequencing data generated from a DAP-seq experiment.
Collapse
Affiliation(s)
- Stephanie Hutin
- Laboratoire de Physiologie Cellulaire et Végétale, CNRS, CEA, Université Grenoble Alpes, INRAE, IRIG, CEA Grenoble, Grenoble, France
| | - Romain Blanc-Mathieu
- Laboratoire de Physiologie Cellulaire et Végétale, CNRS, CEA, Université Grenoble Alpes, INRAE, IRIG, CEA Grenoble, Grenoble, France
| | - Philippe Rieu
- Laboratoire de Physiologie Cellulaire et Végétale, CNRS, CEA, Université Grenoble Alpes, INRAE, IRIG, CEA Grenoble, Grenoble, France
| | - François Parcy
- Laboratoire de Physiologie Cellulaire et Végétale, CNRS, CEA, Université Grenoble Alpes, INRAE, IRIG, CEA Grenoble, Grenoble, France
| | - Xuelei Lai
- Laboratoire de Physiologie Cellulaire et Végétale, CNRS, CEA, Université Grenoble Alpes, INRAE, IRIG, CEA Grenoble, Grenoble, France
- National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, China
| | - Chloe Zubieta
- Laboratoire de Physiologie Cellulaire et Végétale, CNRS, CEA, Université Grenoble Alpes, INRAE, IRIG, CEA Grenoble, Grenoble, France.
| |
Collapse
|
9
|
Dao M, Decramer S, Llanas B, Chauveau D, Nobili F, Ranchin B, Rieu P, Knebelmann B, Hummel A, Servais A. Devenir à l’âge adulte des patients suivis pour un syndrome de Lowe. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Dupont V, Bonnet-Lebrun AS, Boileve A, Debrumetz A, Wynckel A, Braconnier A, Colosio C, Mokri L, Schvartz B, Vuiblet V, Barbe C, Jozwiak M, Rieu P. In Reply to "Abdominal Pressure and Fluid Status After Kidney Transplantation". Kidney Int Rep 2022; 7:1727-1728. [PMID: 35812285 PMCID: PMC9263233 DOI: 10.1016/j.ekir.2022.04.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 04/25/2022] [Indexed: 11/27/2022] Open
Affiliation(s)
- Vincent Dupont
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Department of Nephrology, Centre Hospitalier Universitaire de Reims, Reims, France
- French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT), Reims, France
| | | | - Alice Boileve
- Département de médecine oncologique, Gustave Roussy, Villejuif, France
| | - Alexandre Debrumetz
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Alain Wynckel
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Antoine Braconnier
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Charlotte Colosio
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Laetitia Mokri
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Betoul Schvartz
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Vincent Vuiblet
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Coralie Barbe
- Research on Health University Department, Université de Reims Champagne-Ardenne, Reims, France
| | - Mathieu Jozwiak
- Service de Médecine Intensive Réanimation, CHU de Nice, Nice, France
- Equipe 2 CARRES, UR2CA - Unité de Recherche Clinique Côte d'Azur, Université Côte d’Azur UCA, Nice, France
| | - Philippe Rieu
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
11
|
Attias P, Azzaoui I, El Karoui K, de La Selle A, Sokal A, Chappert P, Grimbert P, Fernandez I, Bouvier M, Samson C, Dahmane D, Rieu P, Nizard P, Fourati S, Sakhi H, Mahévas M. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients. Clin J Am Soc Nephrol 2022; 17:1008-1016. [PMID: 35764393 PMCID: PMC9269639 DOI: 10.2215/cjn.00830122] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 05/16/2022] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES After two doses of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients on dialysis show a defective humoral response, but a third dose could increase anti-SARS-CoV-2 spike IgG titers. Responses could be different in virus-naive and SARS-CoV-2-recovered patients on dialysis. However, characterization of memory B cell response after three doses is lacking. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We evaluated the dynamics of antireceptor binding domain IgG titers and antireceptor binding domain memory B cells until 6 months after two and three doses (administered within 6 months after the second dose) of mRNA vaccine in SARS-CoV-2-recovered and virus-naive dialysis populations. Results were analyzed by ordinary one-way ANOVA, the Kruskal-Wallis test, or the Wilcoxon matched-pairs test as appropriate. RESULTS In total, 108 individuals (59 patients on dialysis and 49 controls) were included. In virus-naive patients on dialysis, antireceptor binding domain IgG response was quantitatively lower after two doses compared with healthy controls, but IgG titers increased by three-fold after three doses (P=0.008). In SARS-CoV-2-recovered patients on dialysis, antireceptor binding domain IgG titers after two doses were significantly higher compared with virus-naive patients on dialysis but did not significantly increase after a third dose. Regarding memory B cell response, we detected receptor binding domain-specific memory B cells at similar proportions in virus-naive patients on dialysis and vaccinated controls after two doses. Moreover, a strong receptor binding domain-specific memory B cell expansion was observed after the third dose in virus-naive patients on dialysis (5.5-fold; P<0.001). However, in SARS-CoV-2-recovered patients on dialysis, antireceptor binding domain memory B cells remained unchanged after the third dose. CONCLUSIONS The third dose of mRNA vaccine given within 6 months after the second dose boosts serologic and memory response in virus-naive patients but not in SARS-CoV-2-recovered patients on dialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells (MEMO-COV2), NCT04402892.
Collapse
Affiliation(s)
- Philippe Attias
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | - Imane Azzaoui
- Department of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 2, Transfusion and pathologies of the red blood cell, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Khalil El Karoui
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Andréa de La Selle
- Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France
| | - Aurélien Sokal
- Department of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 2, Transfusion and pathologies of the red blood cell, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Pascal Chappert
- Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France
- Institut Pasteur, Unité de Virologie Structurale, Centre National de Recherche Scientifique Unité Mixte de Recherche 3569, Paris, France
| | - Philippe Grimbert
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Ignacio Fernandez
- Institut Pasteur, Unité de Virologie Structurale, Centre National de Recherche Scientifique Unité Mixte de Recherche 3569, Paris, France
| | - Magali Bouvier
- Département de Virologie, Bactériologie, Hygiène et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 18, Viruses, Hepatology, Cancer, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Chloé Samson
- Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Djamal Dahmane
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France
| | - Philippe Rieu
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | | | - Slim Fourati
- Département de Virologie, Bactériologie, Hygiène et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 18, Viruses, Hepatology, Cancer, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Hamza Sakhi
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
| | - Matthieu Mahévas
- Department of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France
- Institut National de la Santé et de la Recherche Médical U955, Équipe 2, Transfusion and pathologies of the red blood cell, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France
- Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France
| |
Collapse
|
12
|
Hittinger A, Steelandt A, Kazes I, Clavel P, Canivet E, Rieu P, Salmon JH. AB1036 IS HEMODIALYSIS ENOUGH TO CONTROL GOUT IN CHRONIC TERMINAL RENAL DEFICIENCY PATIENTS? A TEN YEARS RETROSPECTIVE STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundGout is the most common inflammatory rheumatism of industrials countries and chronic renal deficiency is one of the most usual risk factor(1). Uncontrolled gout can cause articular impairment but is also associated with a global and cardiovascular excess mortality, especially in dialysis population(2). International guidelines on gout management remain currently unclear for this particular population(3,4) and current literature data are contradictory on the effectiveness of hemodialysis alone in stemming gout flares.ObjectivesThe objective of this study was to analyze the rate of gout flares, during 5 years on gouty patients who starts hemodialysis, treated or not by hypouricemic drugs.MethodsWe performed an observational, retrospective and multicentric study on gouty patients who started hemodialysis between 2005 and 2015 in two nephrology unit.We recorded demographic, clinical and therapeutic data at the start of hemodialysis and throughout 5 years of follow up.A gout flare was defined as presence of uric acid crystal in articular punction when it was performed, or clinical diagnosed as such with a colchicine prescription. The effectiveness of dialysis was measured by the KT/V ratio measured during gout flares and 3 times per year for each patient correlated with the serum uric acid level.According to the French legislation, no ethics committee approval was requested for such a retrospective survey.Survival analysis by Kaplan - Meier method and bivariate analysis have been performed to study gout flares and their association with clinical or biological factor.ResultsOne hundred eighty two patients have been included, 98/182 (53, 8%) had long term hypouricemic treatment: 88/98 (89%) by allopurinol and 10/98 (11%) by febuxostat.Mean age at dialysis initiation was 68.6 years with a male/female sex ratio of 2.7:1.Sixty-four/182 patients (35.16%) presented at least one gout flare during the follow-up: 42 patients (65%) without hypouricemic treatment and 22 patients (45%) with hypouricemic treatment. Patients on hypouricemic treatment since hemodialysis beginning had significantly less gout flares compared to those without (p = 0.0009) (graphic 1). There was no significant KT/V ratios difference between the 2 populations at the time of gout flares. Hypouricemic treatment was a protective factor for the occurrence of gout attacks (HR: 0.42, 95% CI 0.25 – 0.71) (Table 1).Table 1.Associated factor of gout flares after the beginning of hemodialysis on gouty patientsHR95% CICurrent or active smoking0.920.46-1.86Male0.821.48-1.42Caucasian ethnic0.830.64-1.75Hypouricemic treatment0.420.25-0.71High Blood Pressure1.210.44-3.36Obesity0.840.47-1.51Dyslipidemia0.790.47-1.30Diabetes1.280.78-2.11Cardiac failure1.420.73-2.81HR: Hazard Ratio; CI: Confidence intervalConclusionTherefore hypouricemic treatment at the initiation of hemodialysis seems to be a protective factor against gout flares, which may persist in dialysis patients. Prospectives studies should be performed to confirm these results for this particular gouty population.References[1]Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020 Jul;16(7):380–90.[2]Jaffe DH, Klein AB, Benis A, Flores NM, Gabay H, Morlock R, et al. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatol. 2019;3:11.[3]Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan 1;76(1):29–42.[4]FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. 2020;72(6):744–60.Graphic 1. Survival analysis of gout flaresTIME (years)--: Patients without treatment--: Patients with hypouricemic treatmentDisclosure of InterestsNone declared
Collapse
|
13
|
Chawki S, Buchard A, Sakhi H, Dardim K, El Sakhawi K, Chawki M, Boulanger H, Kofman T, Dahmane D, Rieu P, Attaf D, Ahriz-Saksi S, Masoumi A, Diddaoui AZ, Fromentin L, Michaut P, Nebbad R, Desassis JF, Nicolet L, Sohier-Attias J, Besson F, Boula R, Hafi A, Ghazali A, Lamriben L, Arezki A, Dupuis E, Rifard MK, Joly D, Attias P, El Karoui K. Long-term impact of COVID-19 among maintenance haemodialysis patients. Clin Kidney J 2022; 15:262-268. [PMID: 35140935 PMCID: PMC8522382 DOI: 10.1093/ckj/sfab166] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 09/03/2021] [Indexed: 12/14/2022] Open
Abstract
Background Maintenance haemodialysis (MHD) patients have a high risk of initial mortality from coronavirus disease 2019 (COVID-19). However, long-term consequences of this disease in the MHD population are poorly described. We report the clinical presentation, outcome and long-term follow-up of MHD patients affected by COVID-19 in a multicentric cohort from the Paris, France area. Methods We conducted a retrospective analysis of clinical presentation and long-term follow-up of MHD patients affected by COVID-19 in 19 MHD centres in the Paris, France area. Results In this cohort of 248 patients with an initial mortality rate of 18%, age, comorbidities, dyspnoea and previous immunosuppressive treatment were associated with death at <30 days. Among the 203 surviving patients following the acute phase, long-term follow-up (median 180 days) was available for 189 (93%) patients. Major adverse events occurred in 30 (16%) patients during follow-up, including 12 deaths (6%) after a median of 78 days from onset of symptoms. Overall, cardiovascular events, infections and gastrointestinal bleeding were the main major adverse events. Post-COVID-19 cachexia was observed in 25/189 (13%) patients. Lower initial albuminaemia was significantly associated with this cachexia. No reinfection with severe acute respiratory syndrome coronavirus 2 was observed. Conclusions This work demonstrates the long-term consequences of COVID-19 in MHD patients, highlighting both initial and long-term severity of the disease, including severe cachexia.
Collapse
Affiliation(s)
- Sylvain Chawki
- Institut National de la Santé et de la Recherche Médicale Unité U944, Université de Paris, Paris, France
| | | | - Hamza Sakhi
- Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Créteil, France.,Université Paris-Est Créteil, Institut National de la Santé et de la Recherche MédicaleU955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | | | - Karim El Sakhawi
- Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Créteil, France
| | - Mokhtar Chawki
- Department of Nephrology and Dialysis, Clinique Claude Bernard, Ermont, France
| | - Henri Boulanger
- Department of Nephrology and Dialysis, Clinique de l'Estrée, Stains, France
| | | | - Djamal Dahmane
- Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Créteil, France.,Université Paris-Est Créteil, Institut National de la Santé et de la Recherche MédicaleU955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - Philippe Rieu
- Departement of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | | | - Salima Ahriz-Saksi
- Department of Nephrology and Dialysis, Clinique de l'Estrée, Stains, France
| | | | | | - Luc Fromentin
- Department of Nephrology and Dialysis, Clinique Claude Bernard, Ermont, France
| | - Patrick Michaut
- Department of Nephrology and Dialysis, Clinique Internationale du Parc Monceaux, Paris, France
| | | | | | - Laurence Nicolet
- Department of Nephrology and Dialysis, Centre Edouard Rist, Paris, France
| | | | - Frederic Besson
- Department of Dialysis, Clinique Lambert, La Garenne-Colombes, France
| | - Remy Boula
- Department of Dialysis, Clinique Lambert, La Garenne-Colombes, France
| | - Ali Hafi
- Department of Dialysis, Clinique Lambert, La Garenne-Colombes, France
| | | | - Larbi Lamriben
- Department of Dialysis, Clinique les Martinets, Rueil Malmaison, France
| | - Adem Arezki
- Department of Dialysis, Clinique les Martinets, Rueil Malmaison, France
| | - Emmanuel Dupuis
- Department of Nephrology and Dialysis, American Hospital of Paris, Neuilly-sur-Seine, France
| | - Mohamad-Khair Rifard
- Department of Nephrology and Dialysis, Centre Hospitalier des Quatre Villes, Saint Cloud, France
| | - Dominique Joly
- Department of Adult Nephrology, Assistance Publique des Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Philippe Attias
- Departement of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | - Khalil El Karoui
- Assistance Publique des Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Créteil, France.,Université Paris-Est Créteil, Institut National de la Santé et de la Recherche MédicaleU955, Institut Mondor de Recherche Biomédicale, Créteil, France
| |
Collapse
|
14
|
Dupont V, Bonnet-Lebrun AS, Boileve A, Debrumetz A, Wynckel A, Braconnier A, Colosio C, Mokri L, Schvartz B, Vuiblet V, Barbe C, Jozwiak M, Rieu P. A pilot study on the association between early fluid status indicators after kidney transplantation and graft function recovery. Kidney Int Rep 2022; 7:1416-1419. [PMID: 35685327 PMCID: PMC9171620 DOI: 10.1016/j.ekir.2022.02.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 01/13/2022] [Accepted: 02/08/2022] [Indexed: 12/12/2022] Open
Affiliation(s)
- Vincent Dupont
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Department of Nephrology, Centre Hospitalier Universitaire de Reims, Reims, France
- French Clinical Research Infrastructure Network, Investigation Network Initiative—Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT), Reims, France
- Correspondence: Vincent Dupont, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
| | | | - Alice Boileve
- Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
| | - Alexandre Debrumetz
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Alain Wynckel
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Antoine Braconnier
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Charlotte Colosio
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Laetitia Mokri
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Betoul Schvartz
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Vincent Vuiblet
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Coralie Barbe
- Research on Health University Department, Université de Reims Champagne-Ardenne, Reims, France
| | - Mathieu Jozwiak
- Service de Médecine Intensive Réanimation, CHU Archet 1, Nice, France
- Equipe 2 CARRES, UR2CA—Unité de Recherche Clinique Côte d’Azur, Université Côte d’Azur UCA, Nice, France
| | - Philippe Rieu
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
15
|
Berchtold L, Letouzé E, Alexander MP, Canaud G, Logt AEVD, Hamilton P, Mousson C, Vuiblet V, Moyer AM, Guibert S, Mrázová P, Levi C, Dubois V, Cruzado JM, Torres A, Gandhi MJ, Yousfi N, Tesar V, Viklický O, Hourmant M, Moulin B, Rieu P, Choukroun G, Legendre C, Wetzels J, Brenchley P, Ballarín Castan JA, Debiec H, Ronco P. Corrigendum to Berchtold L, Letouzé E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671-685. Kidney Int 2021; 100:243. [PMID: 34154713 DOI: 10.1016/j.kint.2021.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Lena Berchtold
- Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France; Division of Nephrology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland
| | - Eric Letouzé
- Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, France; Functional Genomics of Solid Tumor, Labex Immuno- Oncology, Equipe Labellisée Ligue Contre le Cancer, Université Paris 13, Paris, France
| | | | - Guillaume Canaud
- Inserm U1151, Necker-Enfants Malades Hospital, Paris, France; University Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Adult Nephrology and Transplantation, Necker-Enfants Malades Hospital, Paris, France
| | - Anne-Els van de Logt
- Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Patrick Hamilton
- Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Christiane Mousson
- Department of Nephrology and Transplantation, University Hospital, Dijon, France
| | - Vincent Vuiblet
- BioSpec T Laboratory, EA 7506 URCA, Reims, France; Nephropathology Department of Biopathology Laboratory, Reims University Hospital, Reims, France; Division of Nephrology, Reims University Hospital, Reims, France
| | - Ann M Moyer
- Department of Laboratory Medicine and Pathology, Personalized Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA
| | | | - Petra Mrázová
- Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Charlène Levi
- Department of Transplantation, Nephrology, and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - Valérie Dubois
- Laboratoire HLA, Etablissement Français du Sang Auvergne Rhone-Alpes, Lyon, France
| | - Josep Maria Cruzado
- Nephrology Department, Hospital Universitari Bellvitge, Bellvitge Research Institute (IDIBELL), Barcelona, Spain; RedInRen, RD16/0009/0031, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Armando Torres
- Hospital Universitario de Canarias, Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Tenerife, Spain
| | - Manish J Gandhi
- Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Nadhir Yousfi
- Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France
| | - Vladimir Tesar
- Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
| | - Ondřej Viklický
- Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | | | - Bruno Moulin
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1109, Strasbourg University, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Department of Nephrology, Strasbourg University Hospital, Strasbourg, France
| | - Philippe Rieu
- Division of Nephrology, Reims University Hospital, Reims, France; Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| | | | - Christophe Legendre
- University Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Adult Nephrology and Transplantation, Necker-Enfants Malades Hospital, Paris, France
| | - Jack Wetzels
- Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Paul Brenchley
- Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | | | - Hanna Debiec
- Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France
| | - Pierre Ronco
- Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France; Department of Nephrology (Day Hospital), AP-HP, Tenon Hospital, Paris, France
| |
Collapse
|
16
|
Gaillard F, Jacquemont L, Roberts V, Albano L, Allard J, Bouvier N, Buchler M, Titeca-Beauport D, Couzi L, Delahousse M, Ducloux D, Durrbach A, Etienne I, Frimat L, Garrouste C, Grimbert P, Hazzan M, Hertig A, Kamar N, Quintrec ML, Mariat C, Moal V, Moulin B, Mousson C, Pouteil-Noble C, Rieu P, Rostaing L, Thierry A, Vigneau C, Macher MA, Hourmant M, Legendre C. Temporal trends in living kidney donation in France between 2007 and 2017. Nephrol Dial Transplant 2021; 36:730-738. [PMID: 31778191 DOI: 10.1093/ndt/gfz229] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Long-term studies have demonstrated a slight increased risk for end-stage renal disease (ESRD) for living kidney donors (LKD). In France, living kidney donation doubled within the past 10 years. We investigated the change in characteristics of LKD between 2007 and 2017 and the adequacy of follow-up. METHODS Data were obtained from the national registry for LKD. We compared characteristics of LKD between two study periods: 2007-11 and 2012-17, and stratified donors by age and relation to recipient. We aggregated four characteristics associated with higher ESRD risk [young age, first-degree relation to recipient, obesity, low glomerular filtration rate (GFR) for age] in a single risk indicator ranging from 0 to 4. RESULTS We included 3483 donors. The proportion of unrelated donors >56 years of age increased significantly. The proportion of related donors <56 years of age decreased significantly. The body mass index and proportion of obese donors did not change significantly. The proportion of donors with low estimated GFR for age decreased significantly from 5% to 2.2% (P < 0.001). The proportion of donors with adequate follow-up after donation increased from 19.6% to 42.5% (P < 0.001). No donor had a risk indicator equal to 4, and the proportion of donors with a risk indicator equal to 0 increased significantly from 19.2% to 24.9% (P < 0.001). CONCLUSIONS An increase in living kidney donation in France does not seem to be associated with the selection of donors at higher risk of ESRD and the proportion of donors with adequate annual follow-up significantly increased.
Collapse
Affiliation(s)
- François Gaillard
- Nephrology and Renal Transplantation Department, Necker Hospital, Paris, France
| | - Lola Jacquemont
- Nephrology and Renal Transplantation Department, CHU Nantes, Nantes, France
| | - Veena Roberts
- Department of Nephrology, St Vincent's Hospital, Melbourne, Australia
| | - Laetitia Albano
- Nephrology and Renal Transplantation Department, Pasteur Hospital, Nice, France
| | - Julien Allard
- Nephrology, Dialysis and Renal Transplantation Department, CHU Limoges, Limoges, France
| | - Nicolas Bouvier
- Nephrology, Dialysis, Transplantation Department, CHU Cote de Nacre, Caen University, Caen, France
| | - Mathias Buchler
- Service de Néphrologie et Immunologie Clinique, CHU Tours, Université de Tours, Tours, France
| | | | - Lionel Couzi
- Nephrology, Transplantation and Dialysis, CHU Bordeaux, CNRS UMR 5164, Bordeaux University, Bordeaux, France
| | - Michel Delahousse
- Nephrology, Dialysis and Renal Transplantation Department, Hospital Foch, Suresnes, France
| | - Didier Ducloux
- Nephrology, Dialysis and Transplantation Department, CHU Besançon, Besançon, France
| | - Antoine Durrbach
- Nephrology and Renal Transplantation Department, Bicêtre Hospital, Le Kremlin Bicêtre, France
| | | | - Luc Frimat
- Nephrology, Dialysis and Transplantation Department, CHU Nancy, Nancy, France
| | - Cyril Garrouste
- Nephrology, Dialysis and Transplantation Department, CHU Clermont Ferrand, Clermont-Ferrand, France
| | - Philippe Grimbert
- Nephrology and Transplantation Department, UPEC University, Créteil, France
| | - Marc Hazzan
- Nephrology Department, University Hospital, Lille, France
| | | | - Nassim Kamar
- Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, INSERM U1043, IFR-BMT, University Paul Sabatier, Toulouse, France
| | - Moglie Le Quintrec
- Nephrology, Transplantation and Dialysis Department, CHU Lapeyronie, and IRMB, INSERM U1183, Montpellier, France
| | - Christophe Mariat
- Nephrology, Dialysis and Transplantation Department, CHU Saint Etienne, Saint Etienne, France
| | - Valérie Moal
- Nephrology and Renal Transplantation, APHM, Marseille, France
| | - Bruno Moulin
- Nephrology and Transplantation Department, University Hospital, Strasbourg, France
| | | | - Claire Pouteil-Noble
- Renal Transplantation Department, Hospices Civils de Lyon and Claude Bernard University, Lyon, France
| | - Philippe Rieu
- Nephrology and Renal Transplantation Department, University Hospital, Reims, France
| | - Lionel Rostaing
- Nephrology, Hemodialysis, Apheresis and Transplantation Department, University Hospital, Grenoble, France
| | - Antoine Thierry
- Nephrology Department, University Hospital and Poitiers University, INSERM U1082, Poitiers, France
| | - Cécile Vigneau
- Nephrology, Dialysis and Transplantation Department, University Hospital, Rennes, France
| | | | - Maryvonne Hourmant
- Nephrology and Renal Transplantation Department, CHU Nantes, Nantes, France
| | - Christophe Legendre
- Nephrology and Renal Transplantation Department, Necker Hospital, Paris, France
| |
Collapse
|
17
|
Gaillard F, Jacquemont L, Lazareth H, Albano L, Barrou B, Bouvier N, Buchler M, Titeca-Beauport D, Couzi L, Delahousse M, Ducloux D, Etienne I, Frimat L, Garrouste C, Glotz D, Grimbert P, Hazzan M, Hertig A, Hourmant M, Kamar N, Le Meur Y, Le Quintrec M, Legendre C, Moal V, Moulin B, Mousson C, Pouteil-Noble C, Rieu P, Ouali N, Rostaing L, Thierry A, Toure F, Chemouny J, Delanaye P, Courbebaisse M, Mariat C. Living kidney donor evaluation for all candidates with normal estimated GFR for age. Transpl Int 2021; 34:1123-1133. [PMID: 33774875 DOI: 10.1111/tri.13870] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 03/01/2021] [Accepted: 03/21/2021] [Indexed: 12/01/2022]
Abstract
Multiple days assessments are frequent for the evaluation of candidates to living kidney donation, combined with an early GFR estimation (eGFR). Living kidney donation is questionable when eGFR is <90 ml/min/1.73 m2 (KDIGO guidelines) or 80 ml/min/1.73 m2 (most US centres). However, age-related GFR decline results in a lower eGFR for older candidates. That may limit the number of older kidney donors. Yet, continuing the screening with a GFR measure increases the number of eligible donors. We hypothesized that in-depth screening should be proposed to all candidates with a normal eGFR for age. We compared the evolution of eGFR after donation between three groups of predonation eGFR: normal for age (Sage ) higher than 90 or 80 ml/min/1.73 m2 (S90 and S80, respectively); across three age groups (<45, 45-55, >55 years) in a population of 1825 French living kidney donors with a median follow-up of 5.9 years. In donors younger than 45, postdonation eGFR, absolute- and relative-eGFR variation were not different between the three groups. For older donors, postdonation eGFR was higher in S90 than in S80 or Sage but other comparators were identical. Postdonation eGFR slope was comparable between all groups. Our results are in favour of in-depth screening for all candidates to donation with a normal eGFR for age.
Collapse
Affiliation(s)
- François Gaillard
- Department of Nephrology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Centre de recherche sur l'inflammation, INSERM UMR1149, CNRS EL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Paris, France
| | - Lola Jacquemont
- Nephrology and Renal Transplantation Department, CHU Nantes, Nantes, France
| | - Hélène Lazareth
- Nephrology Department, Hopital Européen Georges Pompidou, Paris, France
| | - Laetitia Albano
- Nephrology and Renal Transplantation Department, Pasteur Hospital, Nice, France
| | - Benoit Barrou
- Urology Department, Pitié-Salpêtrière, Paris, France
| | - Nicolas Bouvier
- Nephrology, Dialysis, Transplantation Department, CHU Cote de Nacre, Caen University, Caen, France
| | - Mathias Buchler
- Service de Néphrologie et Immunologie Clinique, CHU Tours, Université de Tours, Tours, France
| | | | - Lionel Couzi
- Nephrology, Transplantation and Dialysis, CHU Bordeaux, CNRS UMR 5164, Bordeaux University, Bordeaux, France
| | - Michel Delahousse
- Nephrology, Dialysis and Renal Transplantation Department, Foch Hospital, Suresnes, France
| | - Didier Ducloux
- Nephrology, Dialysis and Transplantation Department, CHU Besançon, Besançon, France
| | | | - Luc Frimat
- Nephrology, Dialysis and Transplantation Department, CHU, Nancy, France
| | - Cyril Garrouste
- Nephrology, Dialysis and Transplantation Department, CHU, Clermont Ferrand, France
| | - Denis Glotz
- Department of Nephrology and Renal Transplantation, Hopital Saint Louis, Paris, France
| | - Philippe Grimbert
- Nephrology and Transplantation Department, UPEC University, Créteil, France
| | - Marc Hazzan
- Nephrology Department, University Hospital, Lille, France
| | - Alexandre Hertig
- Nephrology and Transplantation, Hopital Pitié Salpétrière, Paris, France
| | - Maryvonne Hourmant
- Nephrology and Renal Transplantation Department, CHU Nantes, Nantes, France
| | - Nassim Kamar
- Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, INSERM U1043, IFR-BMT, University Paul Sabatier, Toulouse, France
| | - Yann Le Meur
- Department of Nephrology and Renal Transplantation, CHU Brest, Brest, France
| | - Moglie Le Quintrec
- Nephrology, Transplantation and Dialysis Department, CHU Lapeyronie, and IRMB, INSERM U1183, Montpellier, France
| | - Christophe Legendre
- Nephrology and Renal Transplantation Department, Hopital Necker, Paris, France
| | - Valérie Moal
- Nephrology and Renal Transplantation, APHM, Marseille, France
| | - Bruno Moulin
- Nephrology and Transplantation Department, University Hospital, Strasbourg, France
| | | | - Claire Pouteil-Noble
- Renal Transplantation Department, Hospices Civils de Lyon, Claude Bernard University, Lyon, France
| | - Philippe Rieu
- Nephrology and Renal Transplantation Department, University Hospital, Reims, France
| | - Nacera Ouali
- Nephrology and Renal Transplantation, Hopital Tenon, Paris, France
| | - Lionel Rostaing
- Nephrology, Hemodialysis, Apheresis and Transplantation Department, University Hospital, Grenoble, France
| | - Antoine Thierry
- Nephrology Department, University Hospital and Poitiers University, INSERM U1082, Poitiers, France
| | - Fatouma Toure
- Nephrology, Dialysis and Renal Transplantation Department, CHU, Limoges, France
| | - Jonathan Chemouny
- Nephrology, Dialysis and Transplantation Department, University Hospital, Rennes, France
| | - Pierre Delanaye
- Department of Nephrology-Dialysis-Transplantation, University of Liège (ULg CHU), Liège, Belgium.,Department of Nephrology-Dialysis-Apheresis, Hopital Universitaire Caremeau, Nimes, France
| | - Marie Courbebaisse
- Department of Physiology, European Georges Pompidou Hospital, APHP, INSERM U1151, Paris University, Paris, France
| | - Christophe Mariat
- Nephrology, Dialysis and Renal Transplantation Department, Hôpital Nord, CHU de Saint-Etienne, Jean Monnet University, COMUE Université de Lyon, Lyon, France
| |
Collapse
|
18
|
Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S, Nizard P, El Karoui K. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int 2021; 99:1490-1492. [PMID: 33887317 PMCID: PMC8055946 DOI: 10.1016/j.kint.2021.04.009] [Citation(s) in RCA: 66] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Revised: 04/02/2021] [Accepted: 04/05/2021] [Indexed: 11/23/2022]
Affiliation(s)
- Philippe Attias
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | - Hamza Sakhi
- Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », Créteil, France; University Paris Est Créteil, Institut National de la Santé et de la Recherche Médicale U955, Institut Mondor de Recherche Biomédicale, Equipe 21, Créteil, France
| | - Philippe Rieu
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | - Arvish Soorkia
- Laboratoire de Biologie Médicale ANA-L, Sarcelles, France
| | - David Assayag
- Laboratoire de Biologie Médicale ANA-L, Sarcelles, France
| | - Sabrina Bouhroum
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | - Patrice Nizard
- Laboratoire de Biologie Médicale ANA-L, Sarcelles, France
| | - Khalil El Karoui
- Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », Créteil, France; University Paris Est Créteil, Institut National de la Santé et de la Recherche Médicale U955, Institut Mondor de Recherche Biomédicale, Equipe 21, Créteil, France.
| |
Collapse
|
19
|
Berchtold L, Letouzé E, Alexander MP, Canaud G, Logt AEVD, Hamilton P, Mousson C, Vuiblet V, Moyer AM, Guibert S, Mrázová P, Levi C, Dubois V, Cruzado JM, Torres A, Gandhi MJ, Yousfi N, Tesar V, Viklický O, Hourmant M, Moulin B, Rieu P, Choukroun G, Legendre C, Wetzels J, Brenchley P, Ballarín Castan JA, Debiec H, Ronco P. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int 2021; 99:671-685. [DOI: 10.1016/j.kint.2020.08.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 07/30/2020] [Accepted: 08/13/2020] [Indexed: 12/22/2022]
|
20
|
Dupont V, Debrumetz A, Leguillou A, Morland D, Wynckel A, Colosio C, Mokri L, Schvartz B, Vuiblet V, Larre S, Barbe C, Rieu P. Intra-abdominal hypertension in early post-kidney transplantation period is associated with impaired graft function. Nephrol Dial Transplant 2021; 35:1619-1628. [PMID: 32678426 DOI: 10.1093/ndt/gfaa104] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 04/14/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Moderate hyperhydration is often achieved in the early post-kidney transplantation period. Whether this strategy could lead to the development of intra-abdominal hypertension (IAH) has never been assessed so far. We aimed to study the incidence of IAH after kidney transplantation and its association with graft function recovery. METHODS We conducted a prospective monocentric study among patients undergoing kidney transplantation at the University Hospital of Reims between May 2017 and April 2019. Intravesical pressure (IVP) was monitored every 8 h from Day 0 to 3. RESULTS A total of 107 patients were enrolled. Among 55 patients included in the analysis, 74.5% developed IAH. Body mass index >25 kg/m2 was associated with IAH development {odds ratio [OR] 10.4 [95% confidence interval (CI) 2.0-52.9]; P = 0.005}. A previous history of peritoneal dialysis was protective [OR 0.06 (95% CI 0.01-0.3); P = 0.001]. IAH Grades III and IV occurred in 30.9% of patients and correlated with higher Day 3 creatininaemia (419.6 ± 258.5 versus 232.5 ± 189.4 μmol/L; P = 0.02), higher delayed graft function incidence (41.2 versus 7.9%; P = 0.04), lower Kirchner index measured using scintigraphy (0.47 ± 0.09 versus 0.64 ± 0.09; P = 0.0005) and decreased Day 30 estimated glomerular filtration rate (35.8 ± 18.8 versus 52.5 ± 21.3, P = 0.05). IAH patients had higher fluid balance (P = 0.02). Evolution of IVP correlated with weight gain (P < 0.01) and central venous pressure (P < 0.001). CONCLUSIONS IAH is frequent after kidney transplantation and IAH Grades III and IV are independently associated with impaired graft function. These results question current haemodynamic objectives and raise for the first time interest in intra-abdominal pressure monitoring in these patients. CLINICAL TRIAL NOTATION ClinicalTrials.gov identifier: NCT03478176.
Collapse
Affiliation(s)
- Vincent Dupont
- Department of Nephrology, University Hospital of Reims, Reims, France
| | | | - Adrien Leguillou
- Clinical Research Unit, University Hospital of Reims, Reims, France
| | - David Morland
- Department of Nuclear Medicine, Jean Godinot Institut, Reims, France
| | - Alain Wynckel
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Charlotte Colosio
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Laetitia Mokri
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Betoul Schvartz
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Vincent Vuiblet
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Stephane Larre
- Department of Urology, University Hospital of Reims, Reims, France
| | - Coralie Barbe
- Clinical Research Unit, University Hospital of Reims, Reims, France
| | - Philippe Rieu
- Department of Nephrology, University Hospital of Reims, Reims, France
| |
Collapse
|
21
|
Dupont V, Al-Rifai R, Poitevin G, Ortillon J, Jayyosi L, Terryn C, Francois C, Rieu P, Fritz G, Boulagnon-Rombi C, Fichel C, Schmidt AM, Tournois C, Nguyen P, Touré F. AgeR deletion decreases soluble fms-like tyrosine kinase 1 production and improves post-ischemic angiogenesis in uremic mice. Angiogenesis 2021; 24:47-55. [PMID: 32989644 DOI: 10.1007/s10456-020-09747-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 09/17/2020] [Indexed: 10/23/2022]
Abstract
Peripheral arterial disease occurs more frequently and has a worse prognosis in patients with chronic kidney disease (CKD). The receptor for advanced glycation end products (RAGE) is involved in multiple aspects of uremia-associated vasculopathy. Previous data suggest that the RAGE pathway may promote soluble fms-like tyrosine kinase 1 (sFlt1) production, an anti-angiogenic molecule. Thus, we tested the hypothesis that the deletion of AgeR would decrease sFlt1 production and improve post-ischemic revascularization in uremic condition. We used a well-established CKD model (5/6 nephrectomy) in WT and AgeR-/- C57/Bl6 mice. Hindlimb ischemia was induced by femoral artery ligation. Revascularization was evaluated by complementary approaches: ischemic limb retraction, LASCA imagery, and capillary density. The production of sFlt1 was assessed at both RNA and protein levels. After hindlimb ischemia, uremic mice showed slower functional recovery (p < 0.01), decreased reperfusion (p < 0.01), lower capillary density (p = 0.02), and increased circulating sFlt1 levels (p = 0.03). AgeR deletion restored post-ischemic angiogenesis and was protective from sFlt1 increase in uremic mice. These findings show the main role of RAGE in post-ischemic angiogenesis impairment associated with CKD. RAGE may represent a key target for building new therapeutic approaches to improve the outcome of CKD patients with PAD.
Collapse
Affiliation(s)
- Vincent Dupont
- Department of Nephrology, University Hospital of Reims, Reims, France.
- CNRS UMR 7369, Université de Reims Champagne-Ardenne, Reims, France.
- EA-3801, Université de Reims Champagne-Ardenne, Reims, France.
| | - Rida Al-Rifai
- EA-3801, Université de Reims Champagne-Ardenne, Reims, France
| | - Gael Poitevin
- EA-3801, Université de Reims Champagne-Ardenne, Reims, France
| | - Jeremy Ortillon
- CNRS UMR 7369, Université de Reims Champagne-Ardenne, Reims, France
| | - Laura Jayyosi
- EA-3801, Université de Reims Champagne-Ardenne, Reims, France
| | - Christine Terryn
- Plateforme PICT, Université de Reims Champagne-Ardenne, Reims, France
| | | | - Philippe Rieu
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Günter Fritz
- Institute of Neuropathology, University of Freiburg, Freiburg, Germany
| | - Camile Boulagnon-Rombi
- Laboratoire D'Anatomie Pathologique, Université de Reims Champagne-Ardenne, Reims, France
| | - Caroline Fichel
- Laboratoire D'Anatomie Pathologique, Université de Reims Champagne-Ardenne, Reims, France
| | | | - Claire Tournois
- EA-3801, Université de Reims Champagne-Ardenne, Reims, France
| | - Philippe Nguyen
- EA-3801, Université de Reims Champagne-Ardenne, Reims, France
| | - Fatouma Touré
- Department of Nephrology, University Hospital of Limoges, Limoges, France
- CNRS UMR 7276, INSERM U1262, Université de Limoges, Limoges, France
| |
Collapse
|
22
|
Deliège PG, Bastien J, Mokri L, Guyot-Colosio C, Arndt C, Rieu P. Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature. BMC Ophthalmol 2020; 20:468. [PMID: 33256663 PMCID: PMC7708192 DOI: 10.1186/s12886-020-01741-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 11/23/2020] [Indexed: 11/17/2022] Open
Abstract
Background To report the first case of belatacept-associated multidrug-resistant Cytomegalovirus retinitis in a kidney transplant recipient. Case presentation A 76-year-old African male renal allograft recipient was admitted for acute visual loss of the right eye. Ophthalmological examination of the right eye showed anterior uveitis and vitritis associated with large paravascular haemorrhages and yellow necrotic borders, involving the posterior pole but not the fovea. Both Cytomegalovirus DNA in plasma and aqueous humor were positive. The patient had had several episodes of Cytomegalovirus reactivation subsequent to the introduction of belatacept. His cytomegalovirus was multi-drug resistant, and was treated with maribarir, intravitreal and systemic injections of foscarnet, and anti-Cytomegalovirus human immunoglobulin. In parallel, belatacept was stopped and switched to tacrolimus. Cytomegalovirus DNA became undetectable and there was partial improvement of visual acuity at the last ophthalmologic examination, 18 months after the initial diagnosis of Cytomegalovirus retinitis. Conclusion Cytomegalovirus retinitis is an uncommon opportunistic infection in kidney transplant recipients. Cytomegalovirus retinitis is a serious infection because of the risk of blindness and the occurrence of associated life-threatening opportunistic infections. In view of the recent literature, kidney transplant recipients treated by belatacept immunosuppression may be at increased risk for Cytomegalovirus disease, notably Cytomegalovirus retinitis. The occurrence of Cytomegalovirus retinitis may help improve the selection of patients converted to belatacept.
Collapse
Affiliation(s)
| | - Justine Bastien
- Division of Ophtalmology, University Hospital of Reims, Reims, France
| | - Laetitia Mokri
- Division of Nephrology, University Hospital of Reims, Reims, France
| | | | - Carl Arndt
- Division of Ophtalmology, University Hospital of Reims, Reims, France
| | - Philippe Rieu
- Division of Nephrology, University Hospital of Reims, Reims, France.,Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| |
Collapse
|
23
|
Deliège PG, Braconnier A, Chaix F, Renard Y, Petrache A, Guyot-Colosio C, Kazes I, Mokri L, Barbe C, Rieu P. Skeletal Muscle Index as a Prognostic Marker for Kidney Transplantation in Older Patients. J Ren Nutr 2020; 31:286-295. [PMID: 33139208 DOI: 10.1053/j.jrn.2020.08.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 08/05/2020] [Accepted: 08/30/2020] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE Low skeletal muscle mass has emerged as a risk factor for mortality after liver transplantation. We evaluated the prognostic value of muscle mass on length of hospitalization and adverse outcomes after kidney transplantation in aging end-stage renal disease patients. METHODS One hundred twenty-two patients aged 60 years or older at the time of transplantation were retrospectively analyzed. Skeletal muscle index (SMI), evaluated by computed tomography scan, was calculated from total muscle surface area at L3 vertebral level divided by body height squared. Outcomes were compared according to SMI (namely, length of hospitalization, wound complications, combined endpoint comprising all-cause mortality, and graft failure within 1 year). RESULTS In male patients, by multivariate analysis, a low SMI (<42 cm2/m2) was associated with longer immediate post-transplantation hospitalization (β = 17.03 ± 4.3; P = .0002), longer total hospitalization during the first year (β = 34.3 ± 10.7; P = .002), higher rate of wound complications (odds ratio = 12.1 [1.9-77.0]; P = .008), and higher rate of the combined endpoint of graft loss or death (odds ratio = 3.4 [3.0-399.5]; P = .004). In female patients, low SMI was not associated with length of hospitalization or adverse outcomes after transplantation. CONCLUSION SMI is an independent marker of morbidity and mortality after kidney transplantation in older men and could help thereby nephrologists better select aging candidates for kidney transplantation with a view to improving post-transplant outcomes.
Collapse
Affiliation(s)
| | | | - Floriane Chaix
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Yohann Renard
- Department of General and Digestive Surgey, University Hospital of Reims, Reims, France
| | - Andreaa Petrache
- Department of Nephrology, University Hospital of Reims, Reims, France
| | | | - Isabelle Kazes
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Laetitia Mokri
- Department of Nephrology, University Hospital of Reims, Reims, France
| | - Coralie Barbe
- Department of Biostatistics, University Hospital of Reims, Reims, France
| | - Philippe Rieu
- Department of Nephrology, University Hospital of Reims, Reims, France; Laboratory of Nephrology, UMR CNRS URCA, 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| |
Collapse
|
24
|
Lano G, Braconnier A, Bataille S, Cavaille G, Moussi-Frances J, Gondouin B, Bindi P, Nakhla M, Mansour J, Halin P, Levy B, Canivet E, Gaha K, Kazes I, Noel N, Wynckel A, Debrumetz A, Jourde-Chiche N, Moal V, Vial R, Scarfoglière V, Bobot M, Gully M, Legris T, Pelletier M, Sallee M, Burtey S, Brunet P, Robert T, Rieu P. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. Clin Kidney J 2020; 13:878-888. [PMID: 33354330 PMCID: PMC7743188 DOI: 10.1093/ckj/sfaa199] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD). METHODS We conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality. RESULTS Among the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on diagnosis and a decrease in lymphocyte count were independent risk factors associated with disease severity and with mortality. Chronic use of angiotensin II receptor blockers (ARBs) (18% of patients) was associated with a protective effect on mortality. Treatment with azithromycin and hydroxychloroquine (AZT/HCQ) (46% of patients) were not associated with the composite outcome and with death in univariate and multivariate analyses. CONCLUSIONS COVID-19 is a severe disease with poor prognosis in patients with ESRD. Usual treatment with ARBs seems to be protective of critical evolution and mortality. There is no evidence of clinical benefit with the combination of AZT/HCQ.
Collapse
Affiliation(s)
- Guillaume Lano
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
| | - Antoine Braconnier
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
| | - Stanislas Bataille
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
- Elsan, Phocean Institute of Nephrology, Clinique Bouchard, Marseille, France
| | | | | | - Bertrand Gondouin
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Association des Dialysés Provence et Corse (ADPC), Marseille, France
| | - Pascal Bindi
- Department of Nephrology, Verdun Hospital, Verdun, France
| | - Magued Nakhla
- Department of Nephrology, Laon Hospital, Laon, France
| | - Janette Mansour
- Department of Nephrology, Soissons Hospital, Soissons, France
| | - Pascale Halin
- Department of Nephrology, Charleville-Mézières Hospital, Charleville-Mézières, France
| | - Bénédicte Levy
- Department of Nephrology, Troyes Hospital, Troyes, France
| | - Eric Canivet
- Association Régionale pour la Promotion de la Dialyse à Domicile (ARPDD), Reims, France
| | - Khaled Gaha
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
| | - Isabelle Kazes
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
| | - Natacha Noel
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
| | - Alain Wynckel
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
| | - Alexandre Debrumetz
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
| | - Noemie Jourde-Chiche
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
| | - Valerie Moal
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Romain Vial
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Violaine Scarfoglière
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Mickael Bobot
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
| | - Marion Gully
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Tristan Legris
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Marion Pelletier
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Marion Sallee
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
| | - Stephane Burtey
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
| | - Philippe Brunet
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, INRAe 1260, Marseille, France
| | - Thomas Robert
- Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Marseille, France
| | - Philippe Rieu
- Department of Nephrology and Renal Transplantation, Maison Blanche Hospital, University Hospital of Reims, Reims, France
- Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| |
Collapse
|
25
|
Chawki S, Buchard A, Sakhi H, Dardim K, El Sakhawi K, Chawki M, Boulanger H, Kofman T, Dahmane D, Rieu P, Attaf D, Ahriz-Saksi S, Besson F, Boula R, Hafi A, Massoumi A, Diddaoui AZ, Fromentin L, Michaut P, Nebbad R, Desassis JF, Nicolet L, Ghazali A, Sohier-Attias J, Lamriben L, Adem A, Dupuis E, Rifard MK, Joly D, El Karoui K, Attias P. Treatment impact on COVID-19 evolution in hemodialysis patients. Kidney Int 2020; 98:1053-1054. [PMID: 32750459 PMCID: PMC7395814 DOI: 10.1016/j.kint.2020.07.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Accepted: 07/23/2020] [Indexed: 12/24/2022]
Affiliation(s)
- Sylvain Chawki
- Institut Universitaire d'hématologie, Hôpital Saint-Louis, Institut national de la santé et de la recherche médicale (INSERM), Unité U944, Paris, France
| | | | - Hamza Sakhi
- AP-HP, Department of Nephrology, Hôpital henri Mondor, Institut national de la santé et de la recherche médicale (INSERM) Unité U955, Créteil, France
| | - Karim Dardim
- Association Limousine pour l'Utilisation du Rein artificiel à domicile (ALURAD), Isle, France
| | - Karim El Sakhawi
- AP-HP, Department of Nephrology, Hôpital henri Mondor, Institut national de la santé et de la recherche médicale (INSERM) Unité U955, Créteil, France
| | - Mokhtar Chawki
- Department of Nephrology and Dialysis, Clinique Claude Bernard, Ermont, France
| | - Henri Boulanger
- Department of Nephrology and Dialysis, Clinique de l'Estrée, Stains, France
| | | | - Djamal Dahmane
- AP-HP, Department of Nephrology, Hôpital henri Mondor, Institut national de la santé et de la recherche médicale (INSERM) Unité U955, Créteil, France
| | - Philippe Rieu
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | | | - Salima Ahriz-Saksi
- Department of Nephrology and Dialysis, Clinique de l'Estrée, Stains, France
| | | | - Remy Boula
- Clinique Lambert, Dialysis, La Garenne-Colombes, France
| | - Ali Hafi
- Clinique Lambert, Dialysis, La Garenne-Colombes, France
| | | | | | - Luc Fromentin
- Department of Nephrology and Dialysis, Clinique Claude Bernard, Ermont, France
| | - Patrick Michaut
- Clinique Internationale du Parc Monceau, Nephrology and Dialysis, Paris, France
| | | | | | | | | | - Julie Sohier-Attias
- Centre de Néphrologie Suppléance à l'insuffisance rénale par des techniques autonomes (SIRTA), Argenteuil, France
| | - Larbi Lamriben
- Clinique les Martinets, Dialysis, Rueil Malmaison, France
| | - Arezki Adem
- Clinique les Martinets, Dialysis, Rueil Malmaison, France
| | - Emmanuel Dupuis
- American Hospital of Paris, Nephrology and Dialysis, Neuilly-sur-Seine, France
| | - Mohamad-Khair Rifard
- Centre Hospitalier des Quatre Villes, Nephrology and dialysis, Saint Cloud, France
| | - Dominique Joly
- Assistance publique - hôpitaux de Paris, Hôpital Necker-Enfants Malades, Department of Adult Nephrology, Paris, France
| | - Khalil El Karoui
- AP-HP, Department of Nephrology, Hôpital henri Mondor, Institut national de la santé et de la recherche médicale (INSERM) Unité U955, Créteil, France.
| | - Philippe Attias
- Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France
| | | |
Collapse
|
26
|
Ortillon J, Hézard N, Belmokhtar K, Kawecki C, Terryn C, Fritz G, Kauskot A, Schmidt AM, Rieu P, Nguyen P, Maurice P, Touré F. Receptor for Advanced Glycation End Products is Involved in Platelet Hyperactivation and Arterial Thrombosis during Chronic Kidney Disease. Thromb Haemost 2020; 120:1300-1312. [PMID: 32726852 DOI: 10.1055/s-0040-1714101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Chronic kidney disease (CKD) is associated with a high cardiovascular mortality due to increased rates of vascular lesions and thrombotic events, as well as serum accumulation of uremic toxins. A subgroup of these toxins (advanced glycation end products [AGEs] and S100 proteins) can interact with the receptor for AGEs (RAGE). In this study, we analyzed the impact of CKD on platelet function and arterial thrombosis, and the potential role of RAGE in this process. METHODS Twelve weeks after induction of CKD in mice, platelet function and time to complete carotid artery occlusion were analyzed in four groups of animals (sham-operated, CKD, apolipoprotein E [Apoe]-/-, and Apoe-/-/Ager-/- mice). RESULTS Analysis of platelet function from whole blood and platelet-rich plasma showed hyperactivation of platelets only in CKD Apoe-/- mice. There was no difference when experiments were done on washed platelets. However, preincubation of such platelets with AGEs or S100 proteins induced RAGE-mediated platelet hyperactivation. In vivo, CKD significantly reduced carotid occlusion times of Apoe-/- mice (9.2 ± 1.1 vs. 11.1 ± 0.6 minutes for sham, p < 0.01). In contrast, CKD had no effect on occlusion times in Apoe-/-/Ager-/- mice. Moreover, carotid occlusion in Apoe-/- CKD mice occurred significantly faster than in Apoe-/-/Ager-/- CKD mice (p < 0.0001). CONCLUSION Our results show that CKD induces platelet hyperactivation, accelerates thrombus formation in a murine model of arterial thrombosis, and that RAGE deletion has a protective role. We propose that RAGE ligands binding to RAGE is involved in CKD-induced arterial thrombosis.
Collapse
Affiliation(s)
- Jérémy Ortillon
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix Aging and Vascular Remodelling," Université de Reims Champagne Ardenne, Reims, France
| | - Nathalie Hézard
- Hémostase et Remodelage Vasculaire Post-Ischémique, Laboratoire d'Hématologie, Faculté de Médecine & CHU Reims, Hôpital Robert Debré, Reims, France
| | - Karim Belmokhtar
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix Aging and Vascular Remodelling," Université de Reims Champagne Ardenne, Reims, France
| | - Charlotte Kawecki
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix Aging and Vascular Remodelling," Université de Reims Champagne Ardenne, Reims, France
| | - Christine Terryn
- PICT Platform, Université de Reims Champagne Ardenne, Reims, France
| | - Guenter Fritz
- Institute of Neuropathology, Neurozentrum, University of Freiburg, Freiburg, Germany
| | - Alexandre Kauskot
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Ann Marie Schmidt
- Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, New York, United States
| | - Philippe Rieu
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix Aging and Vascular Remodelling," Université de Reims Champagne Ardenne, Reims, France.,Division of Nephrology, CHU Reims, Reims, France
| | - Philippe Nguyen
- Hémostase et Remodelage Vasculaire Post-Ischémique, Laboratoire d'Hématologie, Faculté de Médecine & CHU Reims, Hôpital Robert Debré, Reims, France
| | - Pascal Maurice
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix Aging and Vascular Remodelling," Université de Reims Champagne Ardenne, Reims, France
| | - Fatouma Touré
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix Aging and Vascular Remodelling," Université de Reims Champagne Ardenne, Reims, France.,Division of Nephrology, CHU Limoges, Limoges, France
| |
Collapse
|
27
|
Jaisson S, Desmons A, Braconnier A, Wynckel A, Rieu P, Gillery P, Garnotel R. An unusually high plasma concentration of homocysteine resulting from a combination of so-called “secondary” etiologies. Clin Biochem 2020; 80:52-55. [DOI: 10.1016/j.clinbiochem.2020.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 03/16/2020] [Accepted: 03/17/2020] [Indexed: 10/24/2022]
|
28
|
Belmokhtar K, Ortillon J, Jaisson S, Massy ZA, Boulagnon Rombi C, Doué M, Maurice P, Fritz G, Gillery P, Schmidt AM, Rieu P, Touré F. Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression. Nephrol Dial Transplant 2020; 34:2018-2030. [PMID: 30778553 DOI: 10.1093/ndt/gfz012] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 01/05/2019] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Chronic kidney disease (CKD) is associated with increased cardiovascular mortality, frequent vascular calcification (VC) and accumulation of uraemic toxins. Advanced glycation end products and S100 proteins interact with the receptor for advanced glycation end products (RAGE). In the present work, we aimed to investigate the role(s) of RAGE in the CKD-VC process. METHODS Apoe-/- or Apoe-/-Ager (RAGE)-/- male mice were assigned to CKD or sham-operated groups. A high-phosphate diet was given to a subgroup of Apoe-/-and Apoe-/-Ager-/- CKD mice. Primary cultures of Ager+/+ and Ager-/- vascular smooth muscle cells (VSMCs) were established and stimulated with either vehicle, inorganic phosphate (Pi) or RAGE ligands (S100A12; 20 µM). RESULTS After 12 weeks of CKD we observed a significant increase in RAGE ligand (AGE and S100 proteins) concentrations in the serum of CKD Apoe-/- mice. Ager messenger RNA (mRNA) levels were 4-fold higher in CKD vessels of Apoe-/- mice. CKD Apoe-/- but not CKD Apoe-/- or Ager-/- mice displayed a marked increase in the VC surface area. Similar trends were found in the high-phosphate diet condition. mRNA levels of Runx2 significantly increased in the Apoe-/- CKD group. In vitro, stimulation of Ager+/+VSMCs with Pi or S100A12 induced mineralization and osteoblast transformation, and this was inhibited by phosphonoformic acid (Pi co-transporters inhibitor) and Ager deletion. In vivo and in vitro RAGE was necessary for regulation of the expression of Pit-1, at least in part through production of reactive oxygen species. CONCLUSION RAGE, through the modulation of Pit-1 expression, is a key molecule in the genesis of VC.
Collapse
Affiliation(s)
- Karim Belmokhtar
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,Laboratoire de Néphrologie, Univesrity of Reims, Faculté de Médecine, Reims, France
| | - Jeremy Ortillon
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,Laboratoire de Néphrologie, Univesrity of Reims, Faculté de Médecine, Reims, France
| | - Stéphane Jaisson
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,University Hospital of Reims, Maison Blanche Hospital, Laboratory of Pediatric Biology and Research, Reims, France
| | - Ziad A Massy
- Division of Nephrology, Ambroise Paré Hospital, APHP, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), UVSQ, Boulogne Billancourt/Paris, France.,Inserm U1018, Team5, CESP, Paris Saclay Unioversityand Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University, UVSQ), Villejuif, France
| | - Camille Boulagnon Rombi
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,CHU Reims, Division of Anatomopathology, Reims, France
| | - Manon Doué
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| | - Pascal Maurice
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| | - Günter Fritz
- Institute of Neuropathology, University of Freiburg, Germany
| | - Philippe Gillery
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,University Hospital of Reims, Maison Blanche Hospital, Laboratory of Pediatric Biology and Research, Reims, France
| | | | - Philippe Rieu
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,Laboratoire de Néphrologie, Univesrity of Reims, Faculté de Médecine, Reims, France.,CHU Reims, Division of Nephrology, Reims, France
| | - Fatouma Touré
- Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.,Laboratoire de Néphrologie, Univesrity of Reims, Faculté de Médecine, Reims, France.,CHU Reims, Division of Nephrology, Reims, France
| |
Collapse
|
29
|
Sigogne M, Kanagaratnam L, Dupont V, Couchoud C, Verger C, Maheut H, Hazzan M, Halimi JM, Barbe C, Canivet E, Petrache A, Dramé M, Rieu P, Touré F. Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a national retrospective study based on two French registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). Nephrol Dial Transplant 2019; 33:2020-2026. [PMID: 29361078 DOI: 10.1093/ndt/gfx364] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 12/01/2017] [Indexed: 11/13/2022] Open
Abstract
Background Pathological features of autosomal dominant polycystic kidney disease (ADPKD) include enlarged kidney volume, higher frequency of digestive diverticulitis and abdominal wall hernias. Therefore, many nephrologists have concerns about the use of peritoneal dialysis (PD) in ADPKD patients. We aimed to analyse survival and technique failure in ADPKD patients treated with PD. Methods We conducted two retrospective studies on patients starting dialysis between 2000 and 2010. We used two French registries: the French Renal Epidemiology and Information Network (REIN) and the French language Peritoneal Dialysis Registry (RDPLF). Using the REIN registry, we compared the clinical features and outcomes of ADPKD patients on PD (n = 638) with those of ADPKD patients on haemodialysis (HD) (n = 4653); with the RDPLF registry, those same parameters were determined for ADPKD patients on PD (n = 797) and compared with those of non-ADPKD patients on PD (n = 12 059). Results A total of 5291 ADPKD patients and 12 059 non-ADPKD patients were included. Analysis of the REIN registry found that ADPKD patients treated with PD represented 10.91% of the ADPKD population. During the study period, PD was used for 11.2% of the non-ADPKD population. Compared with ADPKD patients on HD, ADPKD patients on PD had higher serum albumin levels (38.8 ± 5.3 versus 36.8 ± 5.7 g/dL, P < 0.0001) and were less frequently diabetic (5.31 versus 7.71%, P < 0.03). The use of PD in ADPKD patients was positively associated with the occurrence of a kidney transplantation but not with death [hazard ratio 1.15 (95% confidence interval 0.84-1.58)]. Analysis of the RDPLF registry found that compared with non-ADPKD patients on PD, ADPKD patients on PD were younger and had fewer comorbidities and better survival. ADPKD status was not associated with an increased risk of technique failure or an increased risk of peritonitis. Conclusions According to our results, PD is proposed to a selected population of ADPKD patients, PD does not have a negative impact on ADPKD patients' overall survival and PD technique failure is not influenced by ADPKD status. Therefore PD is a reasonable option for ADPKD patients.
Collapse
Affiliation(s)
- Mickael Sigogne
- Division of Nephrology, University Hospital of Reims, Reims, France
| | | | - Vincent Dupont
- Division of Nephrology, University Hospital of Reims, Reims, France
| | - Cécile Couchoud
- REIN: the French Renal Epidemiology and Information Network Registry (Agence de la biomedecine Paris)
| | - Christian Verger
- RDPLF: the French Language Peritoneal Dialysis Registry, Pontoise, France
| | - Hervé Maheut
- Division of Nephrology, University Hospital of Reims, Reims, France
| | - Marc Hazzan
- Division of Nephrology-University Hospital of Lille and UMR 995, Lille, France
| | - Jean Michel Halimi
- Division of Nephrology and Immunology University Hospital of Tours, Tours, France
| | - Coralie Barbe
- Clinical Investigation Center, University Hospital of Reims, Reims, France
| | - Eric Canivet
- Division of Nephrology, University Hospital of Reims, Reims, France
| | - Andréea Petrache
- Division of Nephrology, University Hospital of Reims, Reims, France
| | - Moustapha Dramé
- Clinical Investigation Center, University Hospital of Reims, Reims, France
| | - Philippe Rieu
- Division of Nephrology, University Hospital of Reims, Reims, France.,Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC)
| | - Fatouma Touré
- Division of Nephrology, University Hospital of Reims, Reims, France.,Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC)
| |
Collapse
|
30
|
Carron C, Pais de Barros JP, Gaiffe E, Deckert V, Adda-Rezig H, Roubiou C, Laheurte C, Masson D, Simula-Faivre D, Louvat P, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Saas P, Ducloux D, Lagrost L, Bamoulid J. End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation. Front Immunol 2019; 10:1630. [PMID: 31474974 PMCID: PMC6706794 DOI: 10.3389/fimmu.2019.01630] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 07/01/2019] [Indexed: 01/04/2023] Open
Abstract
Chronic inflammation in end-stage renal disease (ESRD) is partly attributed to gut bacterial translocation (GBT) due to loss of intestinal epithelium integrity. Increased levels of circulating lipopolysaccharide (LPS) –a surrogate marker of GBT– contribute to maintain a chronic inflammatory state. However, circulating LPS can be neutralized by lipoproteins and transported to the liver for elimination. While ESRD-associated GBT has been widely described, less is known about its changes and impact on clinical outcome after kidney transplantation (KT). One hundred and forty-six renal transplant recipients with serum samples obtained immediately before and 1 year after transplantation (1-Year post KT) were included. Intestinal epithelium integrity (iFABP), total LPS (by measuring 3-hydroxymyristate), LPS activity (biologically active LPS measured by the LAL assay), inflammatory biomarkers (sCD14 and cytokines), lipoproteins and LPS-binding proteins (LBP and phospholipid transfer protein [PLTP] activity) were simultaneously measured. At 1-Year post KT, iFABP decreased but remained higher than in normal volunteers. Total LPS concentration remained stable while LPS activity decreased. Inflammation biomarkers decreased 1-Year post KT. We concomitantly observed an increase in lipoproteins. Higher sCD14 levels before transplantation was associated with lower incidence of acute rejection. Although GBT remained stable after KT, the contemporary increase in lipoproteins could bind circulating LPS and contribute concomitantly to neutralization of LPS activity, as well as improvement in ESRD-associated chronic inflammation. Chronic exposure to LPS in ESRD could promote endotoxin tolerance and explain why patients with higher pre-transplant sCD14 are less prompt to develop acute rejection after transplantation.
Collapse
Affiliation(s)
- Clémence Carron
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France
| | | | - Emilie Gaiffe
- FHU INCREASE, Besançon, France.,INSERM CIC-1431, LabEx LipSTIC, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Fédération Hospitalo-Universitaire INCREASE, Besançon, France
| | - Valérie Deckert
- INSERM, LabEx LipSTIC, Univ. Bourgogne Franche-Comté, LNC UMR1231, Dijon, France
| | - Hanane Adda-Rezig
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France
| | - Caroline Roubiou
- Department of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France
| | - Caroline Laheurte
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,Plateforme de BioMonitoring, EFS Bourgogne Franche-Comté, Besançon, France
| | - David Masson
- INSERM, LabEx LipSTIC, Univ. Bourgogne Franche-Comté, LNC UMR1231, Dijon, France.,CHU Dijon, Biochimie et Service de la Recherche, Dijon, France
| | - Dominique Simula-Faivre
- Department of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France
| | - Pascale Louvat
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,Plateforme de BioMonitoring, EFS Bourgogne Franche-Comté, Besançon, France
| | - Bruno Moulin
- Department of Nephrology, CHU Strasbourg, Dialysis, and Renal Transplantation, Strasbourg, France
| | - Luc Frimat
- Department of Nephrology, CHU Nancy, Dialysis, and Renal Transplantation, Nancy, France
| | - Philippe Rieu
- Department of Nephrology, CHU Reims, Dialysis, and Renal Transplantation, Reims, France
| | - Christiane Mousson
- Department of Nephrology, CHU Dijon, Dialysis, and Renal Transplantation, Dijon, France
| | - Antoine Durrbach
- Department of Nephrology, CHU Kremlin-Bicêtre, Dialysis, and Renal Transplantation, Le Kremlin-Bicêtre, France
| | - Anne-Elisabeth Heng
- Department of Nephrology, CHU Clermont-Ferrand, Dialysis, and Renal Transplantation, Clermont-Ferrand, France
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,FHU INCREASE, Besançon, France.,INSERM CIC-1431, LabEx LipSTIC, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.,Plateforme de BioMonitoring, EFS Bourgogne Franche-Comté, Besançon, France
| | - Didier Ducloux
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,FHU INCREASE, Besançon, France.,INSERM CIC-1431, LabEx LipSTIC, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France
| | - Laurent Lagrost
- INSERM, LabEx LipSTIC, Univ. Bourgogne Franche-Comté, LNC UMR1231, Dijon, France.,CHU Dijon, Biochimie et Service de la Recherche, Dijon, France
| | - Jamal Bamoulid
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,FHU INCREASE, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France
| |
Collapse
|
31
|
Corchia A, Wynckel A, Journet J, Moussi Frances J, Skandrani N, Lautrette A, Zafrani L, Lewandowski E, Reboul P, Vrigneaud L, Djerada Z, Rieu P. Metformin-related lactic acidosis with acute kidney injury: results of a French observational multicenter study. Clin Toxicol (Phila) 2019; 58:375-382. [DOI: 10.1080/15563650.2019.1648816] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
| | | | - Julien Journet
- Department of Nephrology, William Morey Hospital, Chalon-sur-Saône, France
| | - Julie Moussi Frances
- Department of Nephrology, APHM Hôpital de la Conception, CHU Marseille, Marseille, France
| | - Nihel Skandrani
- Department of Nephrology, Belfort Montbéliard Hospital, Montbéliard, France
| | | | - Lara Zafrani
- Intensive Care Unit, Hôpital Saint Louis, Paris, France
| | | | | | - Laurence Vrigneaud
- Department of Internal Medicine & Nephrology, Valenciennes Hospital, Valenciennes, France
| | | | | |
Collapse
|
32
|
Rémy P, Audard V, Natella PA, Pelle G, Dussol B, Leray-Moragues H, Vigneau C, Bouachi K, Dantal J, Vrigneaud L, Karras A, Pourcine F, Gatault P, Grimbert P, Ait Sahlia N, Moktefi A, Daugas E, Rigothier C, Bastuji-Garin S, Sahali D, Aldigier JC, Bataille P, Canaud B, Chauveau D, Combe C, Choukroun G, Cornec-Legall E, Dahan K, Delahousse M, Desvaux D, Deteix P, Durrbach A, Esnault V, Essig M, Fievet P, Frouget T, Guerrot D, Godin M, Gontiers-Picard A, Gosselin M, Hanrotel-Saliou C, Heng AE, Huart A, Humbert A, Kofman T, Hummel A, Lang P, Laville M, Lemeur Y, Malvezzi P, Matignon M, Mesbah R, Moulin B, Muller S, Olagne J, Pardon A, Provot F, Queffeulou G, Plaisier E, Raimbourg Q, Rieu P, Stehlé T, Vanhille P. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney Int 2018; 94:1217-1226. [DOI: 10.1016/j.kint.2018.07.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 06/25/2018] [Accepted: 07/05/2018] [Indexed: 12/15/2022]
|
33
|
Girerd S, Frimat L, Ducloux D, Le Meur Y, Mariat C, Moulin B, Mousson C, Rieu P, Dali-Youcef N, Merckle L, Lepage X, Rossignol P, Girerd N, Jaisser F. EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial. Trials 2018; 19:595. [PMID: 30376884 PMCID: PMC6208100 DOI: 10.1186/s13063-018-2956-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Accepted: 10/01/2018] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Despite advances in immunosuppressive therapy, kidney graft survival has failed to improve during the last decades. Ischemia/reperfusion injury (IRI) is one of the main pathophysiological mechanisms underlying delayed graft function, which is associated with poor long-term graft survival. Due to organ shortage, the proportion of grafts from expanded criteria donors (ECDs) is ever growing. These grafts may particularly benefit from IRI prevention. In preclinical models, mineralocorticoid receptor antagonists (MRAs) have been shown to efficiently prevent IRI. This study aims to assess the effect of MRA administration in the early phase of kidney transplantation (KT) among recipients of ECD grafts on mid-term graft function. METHODS/DESIGN This is a multicenter, double-blind, placebo-controlled, randomized clinical trial. Patients on hemodialysis and undergoing a single or a dual KT from an ECD will be eligible for inclusion. We plan to randomize 132 patients. Included patients will be randomized (1:1) to receive either eplerenone 25 mg every 12 h during 4 days (the first dose being administered just prior to KT) or placebo. The primary outcome is graft function at 3 months, assessed by glomerular filtration rate (GFR, in mL/min/1.73m2) measured using iohexol clearance. Secondary outcomes include (1) proportion of patients with either dialysis dependency or a GFR < 30 mL/min/1.73m2 at 3 months, (2) proportion of patients with immediate, slow, or delayed graft function, (3) proteinuria at 3 months, (4) occurrence of hyperkalemia during the first week following KT, (5) length of hospital stay for the KT, and (6) occurrence of biopsy-proven acute rejection in the first 3 months following KT. Estimated GFR, graft, and patient survival will also be collected at 1, 3, and 10 years via the national database of organ recipients. DISCUSSION Improvement of ECD grafts is a public health priority, since better ECD outcomes could eventually limit organ shortage. MRA administration in the early phase of KT may prevent IRI and subsequently improve mid-term graft function. The trial will also assess the safety of MRA administration in this population, primarily the absence of threatening hyperkalemia. TRIAL REGISTRATION ClinicalTrials.gov, NCT02490904 . Registered on 1 July 2015.
Collapse
Affiliation(s)
- Sophie Girerd
- Transplant Unit, Nephrology Department, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France. .,INSERM U1116, Clinical Investigation Center, Lorraine University, Vandoeuvre-lès-Nancy, France. .,INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.
| | - Luc Frimat
- Transplant Unit, Nephrology Department, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France.,INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France
| | - Didier Ducloux
- INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.,Transplant Unit, Nephrology Department, Besançon University Hospital, Bourgogne Franche-Comté University, Besançon, France
| | - Yannick Le Meur
- Department of Nephrology, Brest University Hospital, Brest University, Brest, France
| | - Christophe Mariat
- Transplant Unit, Nephrology Department, Saint-Etienne University Hospital, Jean Monnet University, Saint-Etienne, France
| | - Bruno Moulin
- INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.,Nephrology and Transplantation Department, Strasbourg University Hospital, Strasbourg University, Strasbourg, France
| | - Christiane Mousson
- Transplant Unit, Nephrology Department, Dijon University Hospital, Bourgogne Franche-Comté University, Dijon, France
| | - Philippe Rieu
- INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.,Transplant Unit, Nephrology Department, Reims University Hospital, Reims Champagne-Ardenne University, Reims, France
| | - Nassim Dali-Youcef
- Department of Biochemistry and Molecular Biology, Strasbourg University Hospital, Strasbourg University, Strasbourg, France.,Department of functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/ CNRS UMR 7104/ INSERM U 964/ Strasbourg University, 1 rue Laurent Fries, 67404, Illkirch, France
| | - Ludovic Merckle
- INSERM U1116, Clinical Investigation Center, Lorraine University, Vandoeuvre-lès-Nancy, France
| | - Xavier Lepage
- INSERM U1116, Clinical Investigation Center, Lorraine University, Vandoeuvre-lès-Nancy, France
| | - Patrick Rossignol
- INSERM U1116, Clinical Investigation Center, Lorraine University, Vandoeuvre-lès-Nancy, France.,INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France
| | - Nicolas Girerd
- INSERM U1116, Clinical Investigation Center, Lorraine University, Vandoeuvre-lès-Nancy, France.,INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France
| | - Frédéric Jaisser
- INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.,INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, Paris, France
| |
Collapse
|
34
|
Dupont V, Al-Rifai R, Ortillon J, Rieu P, Poitevin G, Stephane J, Boulagnon-Rombi C, Tournois C, Nguyen P, Toure F. Rôle de l’urémie et du récepteur aux AGE (RAGE) dans la revascularisation post-ischémique. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
35
|
Dupont V, Kanagaratnam L, Sigogne M, Bechade C, Lobbedez T, Portoles J, Rieu P, Drame M, Touré F. Outcome of polycystic kidney disease patients on peritoneal dialysis: Systematic review of literature and meta-analysis. PLoS One 2018; 13:e0196769. [PMID: 29787614 PMCID: PMC5963788 DOI: 10.1371/journal.pone.0196769] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 04/19/2018] [Indexed: 01/12/2023] Open
Abstract
Background Polycystic kidney disease (PKD) is the most frequent hereditary cause of chronic kidney disease. Peritoneal dialysis (PD) is often avoided for patients with PKD because of the suspected risk of mechanical and infectious complications. Only a few studies have analyzed the outcome of PKD patients on PD with sometimes conflicting results. The purpose of this meta-analysis was to investigate outcomes of patients with PKD treated by PD. Methods A systematic review and meta-analysis were performed examining all studies which included “Polycystic kidney disease” and “Peritoneal dialysis” in their titles, excluding commentaries, letters to the authors and abstracts. PubMed, Embase, Google scholar and Scopus were searched to December 31st 2017. The primary outcome was overall patient survival. Additional outcomes were PD technique survival, incidence of peritonitis and incidence of abdominal wall hernia. Results 9 studies published between 1998 and 2016 were included for analysis with a total of 7,197 patients including 882 PKD patients. Overall survival of PKD patients was found to be better compared to non-PKD patients (HR = 0.70 [95% CI, 0.54–0.92]). There were no statistical differences between PKD and non-PKD patients in terms of peritonitis (OR = 0.86 [95% CI, 0.66–1.12]) and technical survival (HR = 0.98 [95% CI, 0.83–1.16]). There was an increased risk of hernia in PKD patients (OR = 2.28 [95% CI, 1.26–4.12]). Conclusions PKD is associated with a better global survival, an increased risk of abdominal hernia, but no differences in peritonitis rate or technical survival were found. PD is a safe dialysis modality for PKD patients. Properly designed controlled studies are needed to determine whether all PKD patients are eligible for PD or whether some specific criteria should be determined.
Collapse
Affiliation(s)
- Vincent Dupont
- Division of Nephrology, University Hospital of Reims, Reims, France
| | - Lukshe Kanagaratnam
- Department of Research and Innovation, University Hospital of Reims, Reims, France
| | - Mickaël Sigogne
- Division of Nephrology, University Hospital of Reims, Reims, France
| | - Clémence Bechade
- Division of Nephrology, University hospital of Caen, Caen, France
| | - Thierry Lobbedez
- Division of Nephrology, University hospital of Caen, Caen, France
| | - Jose Portoles
- Division of Nephrology, University Hospital of Puerta de Hierro, Madrid, Spain
| | - Philippe Rieu
- Division of Nephrology, University Hospital of Reims, Reims, France
- Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
| | - Moustapha Drame
- Department of Research and Innovation, University Hospital of Reims, Reims, France
| | - Fatouma Touré
- Division of Nephrology, University Hospital of Reims, Reims, France
- Laboratory of Nephrology, UMR CNRS URCA 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
- * E-mail:
| |
Collapse
|
36
|
Dupont V, Debrumetz A, Wynckel A, Rieu P. [How to explain glomerular filtration rate decrease in intra-abdominal hypertension?]. Nephrol Ther 2017; 14:24-28. [PMID: 29173983 DOI: 10.1016/j.nephro.2017.04.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 04/02/2017] [Accepted: 04/04/2017] [Indexed: 11/19/2022]
Abstract
Intra-abdominal hypertension (IAH) is a frequent and serious condition affecting critical care patients. IAH diagnostic needs intravesical pressure (IVP) measurement which is recommended for monitoring patients presenting IAH risk factors. IVP monitoring is probably insufficient in daily practice. This could be explained by lack of knowledge about IAH physiopathology, which leads to absence of therapeutic target. Acute kidney injury (AKI) is the earliest and most described organ dysfunction associated with IAH. Moreover, AKI gravity seems to correlates with IAH severity. Physiopathological aspects explaining glomerular filtration rate (GFR) decrease with IAH are probably multifactorial and not completely understood. The role of renal venous congestion is essential to explain AKI in IAH. GFR decrease may reflect a "glomerular capillary shunt" due to a decrease of renal plasmatic flow. Monitoring IVP in daily practice in patients presenting risk factors of IAH would improve knowledge about this condition and the associated AKI.
Collapse
Affiliation(s)
- Vincent Dupont
- Service de néphrologie, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims cedex, France.
| | - Alexandre Debrumetz
- Service de néphrologie, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims cedex, France
| | - Alain Wynckel
- Service de néphrologie, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims cedex, France
| | - Philippe Rieu
- Service de néphrologie, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims cedex, France
| |
Collapse
|
37
|
Ortillon J, Hezard N, Belmokhtar K, Kawecki C, Terryn C, Schmidt A, Maurice P, Nguyen P, Rieu P, Touré F. Insuffisance rénale chronique et thrombose artérielle : étude de l’implication du vieillissement protéique et du récepteur aux produits de glycation avancée (RAGE). Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Vigneau C, Kolko A, Stengel B, Jacquelinet C, Landais P, Rieu P, Bayat S, Couchoud C. Ten-years trends in renal replacement therapy for end-stage renal disease in mainland France: Lessons from the French Renal Epidemiology and Information Network (REIN) registry. Nephrol Ther 2017; 13:228-235. [DOI: 10.1016/j.nephro.2016.07.453] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 07/11/2016] [Indexed: 11/26/2022]
|
39
|
Vuiblet V, Fere M, Bankole E, Wynckel A, Gobinet C, Birembaut P, Piot O, Rieu P. Raman-based detection of hydroxyethyl starch in kidney allograft biopsies as a potential marker of allograft quality in kidney transplant recipients. Sci Rep 2016; 6:33045. [PMID: 27608775 PMCID: PMC5016807 DOI: 10.1038/srep33045] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Accepted: 07/01/2016] [Indexed: 01/25/2023] Open
Abstract
In brain-dead donor resuscitation, hydroxyethyl starch (HES) use has been associated with presence of osmotic-nephrosis-like lesions in kidney transplant recipients. Our aim was to determine whether the presence of HES in protocol renal graft biopsies at three months (M3) after transplantation is associated with renal graft quality. According to the HES administered to the donor during the procurement procedure, two groups of patients were defined according graft exposition to HES: HES group, (N = 20) and control group (N = 6). Detection and relative quantification of HES was performed by Raman spectroscopy microimaging on M3 protocol renal graft biopsies. Statistical analyses were used to investigate the association between Raman data and graft characteristics. HES spectral signal was revealed negative in the control group, whereas it was positive in 40% of biopsies from the HES group. In the HES group, a stronger HES signal was associated with a lower risk of graft failure measured by the Kidney Donor Risk Index (KDRI) and was correlated with the allograft kidney function. Thus, HES accumulation in donor kidney, as probed by Raman biophotonic technique, is correlated with the quality of donor kidney and consequently the graft renal function and graft survival.
Collapse
Affiliation(s)
- Vincent Vuiblet
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France.,Nephrology division, Maison Blanche University Hospital, Reims, France.,Biopathology Laboratory, Maison Blanche University Hospital, Reims, France
| | - Michael Fere
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France
| | - Ezechiel Bankole
- Department of Anesthesia, Maison Blanche University Hospital, Reims, France
| | - Alain Wynckel
- Nephrology division, Maison Blanche University Hospital, Reims, France
| | - Cyril Gobinet
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France
| | - Philippe Birembaut
- Biopathology Laboratory, Maison Blanche University Hospital, Reims, France
| | - Olivier Piot
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France.,PICT (Cellular and Tissular Imaging Platform), Université de Reims Champagne- Ardenne, Reims, France
| | - Philippe Rieu
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France.,Nephrology division, Maison Blanche University Hospital, Reims, France
| |
Collapse
|
40
|
Desmons A, Jaisson S, Pietrement C, Rieu P, Wynckel A, Gillery P. Homocitrulline: a new marker for differentiating acute from chronic renal failure. Clin Chem Lab Med 2016; 54:73-9. [PMID: 26124058 DOI: 10.1515/cclm-2015-0398] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Accepted: 06/01/2015] [Indexed: 11/15/2022]
Abstract
BACKGROUND Carbamylation is a non-enzymatic post-translational modification of proteins characterized by the addition of isocyanic acid to amino groups. As isocyanic acid mainly originates from the spontaneous dissociation of urea, carbamylation rate is increased during renal failure. The aim of the study was to evaluate serum homocitrulline (HCit), which results from the carbamylation of ε-amino groups of lysine (Lys) residues, in acute renal failure (ARF) and to determine if it could be useful for differentiating acute from chronic renal failure (CRF). METHODS In total, 213 patients with renal failure referred to the nephrology department of the university hospital of Reims were included. Patients were classified into three groups: patients with ARF (ARF group, n=39), patients with CRF complicated with ARF (A/CRF group, n=29) and patients with CRF (CRF group, n=145). Serum HCit concentrations were measured by LC-MS/MS. Concentration kinetics of HCit and urea were studied in patients suffering from ARF. The HCit thresholds distinguishing ARF and CRF were investigated. RESULTS HCit concentrations increased in ARF patients reaching a peak delayed compared to urea concentration peak. HCit concentrations were positively correlated with urea concentrations (r=0.51) and with the time elapsed since the estimated onset of ARF (r=0.57). Serum HCit concentrations were higher (p<0.05) in CRF group compared to ARF group. The receiver operating characteristic curve analysis showed that HCit concentrations <289 μmol/mol Lys were predictive of ARF (Sensitivity: 83%, Specificity: 72%, AUC: 0.856). CONCLUSIONS Our results demonstrate that HCit is a promising biomarker for distinguishing between ARF and CRF patients.
Collapse
|
41
|
Corchia A, Wynckel A, Journet J, Moussi-Francès J, Skandrani N, Lautrette A, Zafrani L, Lewandowski E, Vrigneaud L, Djerada Z, Rieu P. Acidose lactique associée à la metformine avec insuffisance rénale aiguë (IRA) : résultats d’une enquête observationnelle multicentrique en France en 2015. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Ortillon J, Hezard N, Belmokhtar K, Kawecki C, Terryn C, Schmidt A, Maurice P, Nguyen P, Rieu P, Touré F. Étude du rôle de l’urémie et du récepteur aux produits de glycation avancée (RAGE) sur la thrombose artérielle dans un modèle murin. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
43
|
Lakbakbi S, Debrumetz A, Terryn C, Szymezak J, Rieu P, Nguyen P. Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity. Thromb Res 2016; 144:218-23. [DOI: 10.1016/j.thromres.2016.05.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 04/27/2016] [Accepted: 05/18/2016] [Indexed: 10/21/2022]
|
44
|
Hocine A, Belmokhtar K, Bauley K, Jaisson S, Gaha K, Oubaya N, Lesaffre F, Lavaud S, Halin P, Gillery P, Rieu P, Touré F. Serum and Tissue Accumulation of Advanced Glycation End-Products Correlates with Vascular Changes. Perit Dial Int 2016; 35:592-4. [PMID: 26450482 DOI: 10.3747/pdi.2013.00338] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
| | | | | | | | | | - Nadia Oubaya
- Clinical Investigation Center, CHU Reims, France
| | | | | | - Pascale Halin
- Division of Nephrology, Manchester Hospital, Charleville Méziéres, France
| | | | - Philippe Rieu
- Division of Nephrology, CHU Reims, France Laboratory of Nephrology, UMR CNRS URCA 7369, CHU Reims, France
| | - Fatouma Touré
- Division of Nephrology, CHU Reims, France Laboratory of Nephrology, UMR CNRS URCA 7369, CHU Reims, France
| |
Collapse
|
45
|
Jaisson S, Kazes I, Desmons A, Fadel F, Oudart JB, Santos-Weiss ICRD, Millart H, Touré F, Rieu P, Gillery P. Homocitrulline as marker of protein carbamylation in hemodialyzed patients. Clin Chim Acta 2016; 460:5-10. [PMID: 27302313 DOI: 10.1016/j.cca.2016.06.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/08/2016] [Accepted: 06/10/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Homocitrulline (HCit) is a carbamylation-derived product (CDP) that has been identified as a valuable biomarker of morbidity and mortality in patients with chronic kidney disease (CKD). The aim of this study was to determine whether initiation of hemodialysis therapy (HD) could induce variations of HCit concentrations in CKD patients. METHODS Serum HCit concentrations were determined by LC-MS/MS in CKD patients (n=108) just before (M0) and six months (M6) after the initiation of HD therapy. RESULTS Mean HCit concentrations reached 1000μmol/mol Lysine before initiation of HD therapy and decreased by 50% within 6months after HD onset. HCit concentrations remained stable over time as assessed during a 24-months follow-up period. HCit was mostly found in its protein-bound form in HD patients. HCit concentrations obtained at M0 were positively correlated with urea (r=0.58) and carbamylated hemoglobin (r=0.41), and are likely to be promising predictive markers of mortality. However, no correlations were found between HCit concentrations and Kt/V values, suggesting that HCit is not a marker of HD efficiency. CONCLUSION HCit concentrations reflect the intensity of protein carbamylation and are stable over time during HD treatment, making HCit a reliable biomarker in the follow-up of CKD patients.
Collapse
Affiliation(s)
- Stéphane Jaisson
- University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France; University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France.
| | - Isabelle Kazes
- University Hospital of Reims, Nephrology Department, Reims, France
| | - Aurore Desmons
- University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France; University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France
| | - Fouad Fadel
- University Hospital of Reims, Nephrology Department, Reims, France
| | - Jean-Baptiste Oudart
- University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France; University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France
| | | | - Hervé Millart
- University Hospital of Reims, Department of Pharmacology, Reims, France
| | - Fatouma Touré
- University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France; University Hospital of Reims, Nephrology Department, Reims, France
| | - Philippe Rieu
- University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France; University Hospital of Reims, Nephrology Department, Reims, France
| | - Philippe Gillery
- University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France; University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France
| |
Collapse
|
46
|
Crepin T, Gaiffe E, Courivaud C, Roubiou C, Laheurte C, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Saas P, Bamoulid J, Ducloux D. Pre-transplant end-stage renal disease-related immune risk profile in kidney transplant recipients predicts post-transplant infections. Transpl Infect Dis 2016; 18:415-22. [PMID: 27027787 DOI: 10.1111/tid.12534] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 11/26/2015] [Accepted: 01/31/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND End-stage renal disease (ESRD) is associated with premature aging of the T-cell system. Nevertheless, the clinical significance of pre-transplant ESRD-related immune senescence is unknown. METHODS We studied whether immune risk phenotype (IRP), a typical feature of immune senescence, may affect post-transplant infectious complications. A total of 486 patients were prospectively studied during the first year post transplant. IRP was defined as positive cytomegalovirus serology with at least 1 of the following criteria: CD4/CD8 ratio <1 and/or CD8 T-cell count >90th percentile. RESULTS We found that 47 patients (9.7%) had pre-transplant IRP. IRP+ patients did not differ from IRP- patients for any clinical characteristics, but exhibited more pronounced immune senescence. Both opportunistic infections (43% vs. 6%, P < 0.001) and severe bacterial infection (SBI) (40% vs. 25%, P = 0.028) were more frequent in IRP(+) patients. In multivariate analysis, IRP was predictive of both opportunistic infection (hazard ratio [HR] 2.97 [95% confidence interval {CI} 1.53-5.76], P = 0.001), and SBI (HR 2.33 [95% CI 1.34-3.92], P = 0.008). Acute rejection rates were numerically much lower in IRP+ patients. A total of 418 patients (86%) had biological evaluation 1 year post transplant. Among 41 IRP+ patients, 35 (85%) remained IRP+ 1 year post transplant. CONCLUSION Pre-transplant IRP is associated with an increased risk of post-transplant infection.
Collapse
Affiliation(s)
- T Crepin
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France.,Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.,Structure Fédérative de Recherche, SFR FED4234, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - E Gaiffe
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France.,CIC Biothérapie, INSERM CIC1431, CHU Besançon, Besançon, France
| | - C Courivaud
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France.,Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.,Structure Fédérative de Recherche, SFR FED4234, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - C Roubiou
- Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.,Structure Fédérative de Recherche, SFR FED4234, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - C Laheurte
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France.,Plateforme de Biomonitoring, EFS Bourgogne Franche-Comté, CIC 1431/UMR1098, Besançon, France
| | - B Moulin
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Strasbourg, Strasbourg, France
| | - L Frimat
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Nancy, Nancy, France
| | - P Rieu
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Reims, Reims, France
| | - C Mousson
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Dijon, Dijon, France
| | - A Durrbach
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Kremlin-Bicêtre, Le Kremlin-Bicêtre, France
| | - A-E Heng
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - P Saas
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France.,Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.,Structure Fédérative de Recherche, SFR FED4234, Besançon, France.,CIC Biothérapie, INSERM CIC1431, CHU Besançon, Besançon, France.,Plateforme de Biomonitoring, EFS Bourgogne Franche-Comté, CIC 1431/UMR1098, Besançon, France
| | - J Bamoulid
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France.,Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.,Structure Fédérative de Recherche, SFR FED4234, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - D Ducloux
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France.,Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.,Structure Fédérative de Recherche, SFR FED4234, Besançon, France.,Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France.,CIC Biothérapie, INSERM CIC1431, CHU Besançon, Besançon, France
| |
Collapse
|
47
|
Bertocchio JP, Barbe C, Lavaud S, Toupance O, Nazeyrollas P, Jaisser F, Rieu P. Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A. PLoS One 2016; 11:e0153635. [PMID: 27088859 PMCID: PMC4835088 DOI: 10.1371/journal.pone.0153635] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Accepted: 04/01/2016] [Indexed: 12/22/2022] Open
Abstract
Background Animal studies have highlighted the role of vascular mineralocorticoid receptor during Cyclosporine A-induced nephrotoxicity. Mineralocorticoid receptor antagonists could improve kidney survival but are not commonly used during renal impairment and in association with several immunosuppressive drugs due to a supposed higher risk of adverse events. We tested the tolerance of eplerenone according to its expected adverse events: hyperkalemia, metabolic acidosis, hypotension, acute kidney failure, or any other adverse event. Methods We conducted a single-center, prospective, open-label study in 31 kidney-transplant recipients with impaired renal function (30 and 50 mL/min/1.73m2) and receiving cyclosporine A. All patients received eplerenone 25 mg/d for 8 weeks. Serum potassium, renal function and expected adverse events were closely monitored. Results Eight patients experienced mild hyperkalemia (>5 mmol/L), one moderate hyperkalemia (>5.5 mmol/L) and had to receive potassium-exchange resin. No severe hyperkalemia (>6 mmol/L) occurred. One acute kidney failure was observed, secondary to diarrhea. Basal serum potassium and bicarbonate were independently associated with a higher risk of developing mild hyperkalemia (>5 mmol/L) under treatment (OR 6.5, p = 0.003 and 0.7, p = 0.007, respectively). A cut-off value of 4.35 mmol/L for basal serum potassium was the best factor to predict the risk of developing mild hyperkalemia (>5 mmol/L). Conclusions Until eGFR falls to 30 mL/min/1.73m2, eplerenone could be safely given to kidney-transplant recipients receiving cyclosporine A, if kalemia is closely monitored. When renal function is impaired and if basal kalemia is >4.35 mmol/L, then clinicians should properly balance risk and benefit of eplerenone use and offer dietary advice. An adequately powered prospective randomized study is now needed to test its efficiency (and safety) in this population. Trial Registration ClinicalTrials.gov NCT01834768
Collapse
Affiliation(s)
- Jean-Philippe Bertocchio
- Nephrology, Dialysis and Transplantation Unit, Reims University Hospital, Avenue Cognacq Jay, 51092 Reims CEDEX, France.,INSERM UMRS 1138 -Team 1, Research Centre of Cordeliers, 15 rue de l'école de médecine, 75006 Paris CEDEX, France
| | - Coralie Barbe
- Biostatistics and methodology unit, Reims University Hospital, Avenue Cognacq Jay, 51092 Reims CEDEX, France
| | - Sylvie Lavaud
- Nephrology, Dialysis and Transplantation Unit, Reims University Hospital, Avenue Cognacq Jay, 51092 Reims CEDEX, France
| | - Olivier Toupance
- Nephrology, Dialysis and Transplantation Unit, Reims University Hospital, Avenue Cognacq Jay, 51092 Reims CEDEX, France
| | - Pierre Nazeyrollas
- Biostatistics and methodology unit, Reims University Hospital, Avenue Cognacq Jay, 51092 Reims CEDEX, France
| | - Frederic Jaisser
- INSERM UMRS 1138 -Team 1, Research Centre of Cordeliers, 15 rue de l'école de médecine, 75006 Paris CEDEX, France
| | - Philippe Rieu
- Nephrology, Dialysis and Transplantation Unit, Reims University Hospital, Avenue Cognacq Jay, 51092 Reims CEDEX, France
| |
Collapse
|
48
|
Bertocchio JP, Mohajer M, Gaha K, Ramont L, Maheut H, Rieu P. Modifications to bicarbonate conductivity: A way to increase phosphate removal during hemodialysis? Proof of concept. Hemodial Int 2016; 20:601-609. [PMID: 27060343 DOI: 10.1111/hdi.12423] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Introduction Hyperphosphatemia and cardiovascular mortality are associated particularly with end-stage renal disease. Available therapeutic strategies (i.e., diet restriction, calcium [or not]-based phosphate binders, calcimimetics) are associated with extrarenal blood purification. Compartmentalization of phosphate limits its depuration during hemodialysis. Several studies suggest that plasmatic pH is involved in the mobilization of phosphate from intracellular to extracellular compartments. Consequently, the efficiency of modified bicarbonate conductivity to purify blood phosphate was tested. Methods Ten hemodialysis patients with chronic hyperphosphatemia (>2.1 mmol/L) were included in the two three-sessions-per week periods. Bicarbonate concentration was fixed at 40 mmol/L and 30 mmol/L in the first and second periods, respectively. Phosphate depuration was evaluated by phosphate mobilization clearance (KM ). Findings Although bicarbonatemia was lower during the second period (21.0 ± 2.7 vs. 24.4 ± 3.1 mmol/L, P < 0.01), no difference was observed in phosphatemia (2.4 ± 0.5 vs. 2.3 ± 0.4 mmol/L, P = NS). The in-session variation of phosphate was lower (-1.45 ± 0.42 vs. -1.58 ± 0.44 mmol/L, P < 0.05) and KM was higher during the second period (82.94 ± 38.00 vs. 69.74 ± 24.48 mL/min, P < 0.05). Discussion The decrease of in-session phosphate and the increase in KM reflect phosphate refilling during hemodialysis. Thus, modulation of serum bicarbonate may play a role in controlling the phosphate pool. Even though correcting metabolic acidosis during hemodialysis remains important, alkaline excess can impair phosphate mobilization clearance. Clinical trials are needed to test the efficiency and relevance of a strategy where bicarbonatemia is corrected less at the beginning of sessions.
Collapse
Affiliation(s)
| | - Médérick Mohajer
- Nephrology, Hemodialysis and Transplantation Unit, Reims University Hospital, Reims, France
| | - Khaled Gaha
- Nephrology, Hemodialysis and Transplantation Unit, Reims University Hospital, Reims, France
| | - Laurent Ramont
- CHU de Reims, Laboratoire Central de Biochimie, 51092, Reims, France.,Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), 51095, Reims, France
| | - Hervé Maheut
- Nephrology, Hemodialysis and Transplantation Unit, Reims University Hospital, Reims, France
| | - Philippe Rieu
- Nephrology, Hemodialysis and Transplantation Unit, Reims University Hospital, Reims, France.,Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), 51095, Reims, France
| |
Collapse
|
49
|
Belmokhtar K, Robert T, Ortillon J, Braconnier A, Vuiblet V, Boulagnon-Rombi C, Diebold MD, Pietrement C, Schmidt AM, Rieu P, Touré F. Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis. Arterioscler Thromb Vasc Biol 2016; 36:800-9. [PMID: 26988587 DOI: 10.1161/atvbaha.115.306349] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 02/29/2016] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Cardiovascular disease is the leading cause of death in patients with end-stage renal disease. Serum amyloid A (SAA) is an acute phase protein and a binding partner for the multiligand receptor for advanced glycation end products (RAGE). We investigated the role of the interaction between SAA and RAGE in uremia-related atherogenesis. APPROACH AND RESULTS We used a mouse model of uremic vasculopathy, induced by 5 of 6 nephrectomy in the Apoe(-/-) background. Sham-operated mice were used as controls. Primary cultures of Ager(+/+) and Ager(-/-) vascular smooth muscle cells (VSMCs) were stimulated with recombinant SAA, S100B, or vehicle alone. Relevance to human disease was assessed with human VSMCs. The surface area of atherosclerotic lesions at the aortic roots was larger in uremic Apoe(-/-) than in sham-operated Apoe(-/-) mice (P<0.001). Furthermore, atherosclerotic lesions displayed intense immunostaining for RAGE and SAA, with a pattern similar to that of α-SMA. Ager transcript levels in the aorta were 6× higher in uremic animals than in controls (P<0.0001). Serum SAA concentrations were higher in uremic mice, not only after 4 weeks of uremia but also at 8 and 12 weeks of uremia, than in sham-operated animals. We investigated the functional role of RAGE in uremia-induced atherosclerosis further, in animals lacking RAGE. We found that the induction of uremia in Apoe(-/-) Ager(-/-) mice did not accelerate atherosclerosis. In vitro, the stimulation of Ager(+/+) but not of Ager(-/-) VSMCs with SAA or S100B significantly induced the production of reactive oxygen species, the phosphorylation of AKT and mitogen-activated protein kinase-extracellular signal-regulated kinases and cell migration. Reactive oxygen species inhibition with N-acetyl cysteine significantly inhibited both the phosphorylation of AKT and the migration of VSMCs. Similar results were obtained for human VSMCs, except that the phosphorylation of mitogen-activated protein kinase-extracellular signal-regulated kinases, rather than of AKT, was subject to specific redox-regulation by SAA and S100B. Furthermore, human aortic atherosclerotic sections were positively stained for RAGE and SAA. CONCLUSIONS Uremia upregulates SAA and RAGE expression in the aortic wall and in atherosclerotic lesions in mice. Ager(-/-) animals are protected against the uremia-induced acceleration of atherosclerosis. SAA modulates the functions of murine and human VSMCs in vitro in a RAGE-dependent manner. This study, therefore, identifies SAA as a potential new uremic toxin involved in uremia-related atherosclerosis through interaction with RAGE.
Collapse
Affiliation(s)
- Karim Belmokhtar
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Thomas Robert
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Jeremy Ortillon
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Antoine Braconnier
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Vincent Vuiblet
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Camille Boulagnon-Rombi
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Marie Danièle Diebold
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Christine Pietrement
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Ann Marie Schmidt
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Philippe Rieu
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.)
| | - Fatouma Touré
- From the UFR Medecine, Laboratoire de néphrologie, Faculté de Médecine, Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France (K.B., T.R., J.O., V.V., M.D.D., C.P., P.R., F.T.); Division of Nephrology (T.R., A.B., V.V., P.R., F.T.), Division of Anatomopathology (C.B.-R., M.D.D.), and Division of Pediatrics (C.P.), CHU Reims, Reims, France; and Diabetes Research Program, New York University, New York (A.M.S.).
| |
Collapse
|
50
|
Bamoulid J, Courivaud C, Crepin T, Carron C, Gaiffe E, Roubiou C, Laheurte C, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Rebibou JM, Saas P, Ducloux D. Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients. Kidney Int 2016; 89:1136-1143. [PMID: 27083287 DOI: 10.1016/j.kint.2015.12.044] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Revised: 11/26/2015] [Accepted: 12/17/2015] [Indexed: 12/25/2022]
Abstract
Lack of clear identification of patients at high risk of acute rejection hampers the ability to individualize immunosuppressive therapy. Here we studied whether thymic function may predict acute rejection in antithymocyte globulin (ATG)-treated renal transplant recipients in 482 patients prospectively studied during the first year post-transplant of which 86 patients experienced acute rejection. Only CD45RA(+)CD31(+)CD4(+) T cell (recent thymic emigrant [RTE]) frequency (RTE%) was marginally associated with acute rejection in the whole population. This T-cell subset accounts for 26% of CD4(+) T cells. Pretransplant RTE% was significantly associated with acute rejection in ATG-treated patients (hazard ratio, 1.04; 95% confidence interval, 1.01-1.08) for each increased percent in RTE/CD4(+) T cells), but not in anti-CD25 monoclonal (αCD25 mAb)-treated patients. Acute rejection was significantly more frequent in ATG-treated patients with high pretransplant RTE% (31.2% vs. 16.4%) or absolute number of RTE/mm(3) (31.7 vs. 16.1). This difference was not found in αCD25 monclonal antibody-treated patients. Highest values of both RTE% (>31%, hazard ratio, 2.50; 95% confidence interval, 1.09-5.74) and RTE/mm(3) (>200/mm(3), hazard ratio, 3.71; 95% confidence interval, 1.59-8.70) were predictive of acute rejection in ATG-treated patients but not in patients having received αCD25 monoclonal antibody). Results were confirmed in a retrospective cohort using T-cell receptor excision circle levels as a marker of thymic function. Thus, pretransplant thymic function predicts acute rejection in ATG-treated patients.
Collapse
Affiliation(s)
- Jamal Bamoulid
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France; Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - Cécile Courivaud
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France; Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - Thomas Crepin
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France; Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - Clémence Carron
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France
| | - Emilie Gaiffe
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France; CHU Besançon, CIC Biothérapie, INSERM CIC1431, Besançon, France
| | - Caroline Roubiou
- Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France; Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France
| | - Caroline Laheurte
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, CIC 1431/UMR1098, Besançon, France
| | - Bruno Moulin
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Strasbourg, Strasbourg, France
| | - Luc Frimat
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Nancy, Nancy, France
| | - Philippe Rieu
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Reims, Reims, France
| | - Christiane Mousson
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Dijon, Dijon, France
| | - Antoine Durrbach
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Kremlin-Bicêtre, Le Kremlin-Bicêtre, France
| | - Anne-Elisabeth Heng
- Department of Nephrology, Dialysis, and Renal Transplantation, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Jean-Michel Rebibou
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Department of Nephrology, Dialysis, and Renal Transplantation, CHU Dijon, Dijon, France
| | - Philippe Saas
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France; CHU Besançon, CIC Biothérapie, INSERM CIC1431, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, CIC 1431/UMR1098, Besançon, France
| | - Didier Ducloux
- INSERM, UMR1098, Federation hospitalo-universitaire INCREASE, Besançon, France; Faculté de Médecine et de Pharmacie, University Bourgogne Franche-Comté, Besançon, France; Structure Fédérative de Recherche, Besançon, France; Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, Besançon, France; CHU Besançon, CIC Biothérapie, INSERM CIC1431, Besançon, France.
| |
Collapse
|